[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 339
1. Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G: Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology; 2010 Apr;56(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.
  • AIMS: To study the relevance of periostin, known to be involved in epithelial-mesenchymal transition (EMT), in hepatocellular and bile duct cancer.
  • METHODS AND RESULTS: Immunohistochemical periostin expression was semiquantitatively analysed in normal liver tissue (n = 20), hepatocellular carcinoma (HCC; n = 91), liver-cell adenoma (n = 9), focal nodular hyperplasia (n = 13) and bile duct carcinomas (BDC; n = 116) using tissue microarrays.
  • Importantly, there was no strong periostin expression in benign liver tumours.
  • Strong stromal periostin expression was detected in 78/116 (67.2%) BDC and strong epithelial expression in 39/116 (33.6%) BDC. pT stage, differentiation grade and proliferation rate in primary BDC were independent of periostin expression.
  • [MeSH-major] Adenoma / metabolism. Bile Duct Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Cell Adhesion Molecules / metabolism. Focal Nodular Hyperplasia / metabolism. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Immunohistochemistry. Liver / metabolism. Liver / pathology. Male. Middle Aged. Prognosis. Survival Rate. Switzerland / epidemiology. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459570.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human
  •  go-up   go-down


2. Kim H, Ahn YC, Park HC, Lim DH, Nam H: Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer. J Thorac Oncol; 2010 Apr;5(4):526-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer.
  • INTRODUCTION: Retrospective analyses were performed on the patients with primary or metastatic lung cancer, who were treated with hypofractionated stereotactic radiation therapy (HSRT).
  • METHODS: HSRT was applied to 43 patients since 2001 till 2007: 16 patients were with stage I primary lung cancer and 27 were with metastasis.
  • CONCLUSIONS: In HSRT for primary or metastatic lung cancers, smaller tumor size was significant prognostic factor for higher local control.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Gastrointestinal Neoplasms / radiotherapy. Head and Neck Neoplasms / radiotherapy. Liver Neoplasms / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome


3. Duan YW, Huang Y, Cai LQ, Duan Q, Zhu YS: Inhibition of tumor growth and tumor metastasis by a Chinese herbal formula--ZYD88, in an animal model with metastatic Lewis lung carcinoma. Oncol Rep; 2007 Jun;17(6):1391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of tumor growth and tumor metastasis by a Chinese herbal formula--ZYD88, in an animal model with metastatic Lewis lung carcinoma.
  • In the present study, we determined the effectiveness of ZYD88, a Chinese herbal formula, in the inhibition of tumor growth and distant tumor metastases to the lung and liver in an animal model with metastatic Lewis lung carcinoma (LLC).
  • Treatment with ZYD88 in adult C57BL/6 mice with metastatic LLC produced dose-dependent deceases in primary tumor weight, the mitotic tumor cell number, microvessel density, distant tumor metastases and red blood cell immune complexes, while it significantly increased tumor necrosis, thymus cortical thickness, the thymus medullar reticular epithelial cell (REC) number, and the activity of red blood cell C3b receptors.
  • Although cyclophosphamide inhibited tumor growth, it had no significant effects on distant tumor metastases, thymus cortical thickness, the thymus medullar REC number, red blood cell C3b receptor activity and red blood cell immune complexes.
  • [MeSH-major] Carcinoma, Lewis Lung / prevention & control. Carcinoma, Lewis Lung / secondary. Drugs, Chinese Herbal / therapeutic use. Liver Neoplasms / prevention & control. Liver Neoplasms / secondary. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Animals. Capillaries / drug effects. Cell Proliferation / drug effects. Disease Models, Animal. Immunity / drug effects. Mice. Mice, Inbred C57BL. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487396.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / ZYD88 herbal formula
  •  go-up   go-down


Advertisement
4. Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ: Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother; 2008 Jan;31(1):72-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
  • Vaccination consisted of autologous cells cultured from primary tumor or resected metastasis, transduced to express B7.1 surface molecule and then irradiated.
  • [MeSH-major] Antigens, CD80 / immunology. Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / therapy. Interleukin-2 / therapeutic use. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Interferon-gamma / metabolism. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / metabolism. Liver / drug effects. Liver / immunology. Liver / pathology. Male. Middle Aged. Neoplasm Staging. Skin / drug effects. Skin / immunology. Skin / pathology. Survival Analysis. Transfection. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18157014.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA 82059-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Cancer Vaccines; 0 / Interleukin-2; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


5. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2008 Jan 1;26(1):83-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: A retrospective review of 360 patients with International Federation of Gynecology and Obstetrics stage IV EOC who underwent primary surgery followed by six cycles of intravenous platinum/paclitaxel was performed.
  • Multivariate regression analysis revealed that histology, malignant pleural effusion, intraparenchymal liver metastasis, and residual tumor size were significant prognostic variables.
  • Patients with less than 5.0 cm of disease initially and significant disease and/or comorbidities precluding microscopic cytoreduction may be considered for alternative therapeutic options other than primary cytoreduction.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Follow-Up Studies. Humans. Medical Records. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pleural Effusion, Malignant / etiology. Postoperative Complications / etiology. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 1;26(10):1771-2; author reply 1772 [18375912.001]
  • (PMID = 18025437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Savelov NA, Petrovichev NN, Anurova OA, Pavlovskaia AI, Tatosian AG: [Immunohistochemical diagnosis of metastases of small round cell carcinomas with undetected primary focus]. Arkh Patol; 2006 Mar-Apr;68(2):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical diagnosis of metastases of small round cell carcinomas with undetected primary focus].
  • 17 small round cell tumors of unkown primary site were studied.
  • One of the following diagnosis was obtained in 14 cases (82.4%): small cell carcinoma, Merkel cell carcinoma, melanoma, Ewing sarcoma family tumor.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Small Cell / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / secondary. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752503.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Wu D, Bao WG, Ding YH: [Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer caused ascites]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Dec;25(12):1066-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer caused ascites].
  • OBJECTIVE: To observe the clinical efficacy of Xiaoshui Decoction (XSD) in treating ascites in patients suffered from primary liver cancer of Pi-deficiency with damp harassment syndrome (PDDHS) as well as to study the effect through the experiment in mice.
  • METHODS: Sixty-one patients confirmed to be primary liver cancer of PDDHS and accompanied with ascites were randomly divided into the treated group (n=33) and the control group (n=28).
  • Experimental study showed that on the two mice models of ascites induced by inoculating two kinds of tumor cell, the effect of XSD was superior to that of the control group in aspects of reducing ascites and prolonging survival period, showing significant difference (P < 0.05).
  • CONCLUSION: Satisfactory short-term efficacy in treating primary liver cancer with ascites of the Pi-deficiency with damp harassment syndrome could be obtained by XSD.
  • XSD can also improve the symptoms and QOL of patients, therefore, it is an effective and reliable remedy for treatment of primary liver cancer with ascites.


8. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2008 Jan;19(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer.
  • Primary end point was overall survival (OS).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938425.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; 80061L1WGD / Cimetidine; 8GTS82S83M / Diphenhydramine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer stem cells have been isolated from several solid tumors including prostate, colon, liver, breast, and ovarian cancer.
  • The aims of this study were to investigate the expression of the CD133-1 and CD133-2 epitopes in primary ovarian tumors and to biologically characterize CD133(+) ovarian cancer cells, also according to clinicopathologic parameters.
  • Tissue specimens were obtained at primary surgery from 41 ovarian carcinomas; eight normal ovaries and five benign ovarian tumors were also collected.
  • FACS (fluorescence activated cell sorting) analysis enabled the selection of CD133(+) cells, whose epithelial origin was confirmed by immunofluorescence analysis with monoclonal anti-cytokeratin 7.
  • The percentages of CD133-1- and CD133-2-expressing cells were significantly lower in normal ovaries/benign tumors with respect to those in ovarian carcinoma.
  • Both the percentages of CD133-1- and CD133-2-expressing cells were significantly lower in omental metastases than in primary ovarian cancer (P = 0.009 and 0.007 for CD133-1- and CD133-2-expressing cells, respectively).
  • There seems not to be any difference in the distribution of the percentage of CD133-1- and CD133-2-expressing cells according to clinicopathologic parameters and response to primary chemotherapy.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


10. Suenaga M, Matsushita K, Kawamata N, Kukita T, Hamakawa Y, Gejima K, Onodera R, Sato T, Yamaguchi A, Inoue H, Arimura K, Arima N, Yoshida H, Tei C: True malignant histiocytosis with trisomy 9 following primary mediastinal germ cell tumor. Acta Haematol; 2006;116(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] True malignant histiocytosis with trisomy 9 following primary mediastinal germ cell tumor.
  • A diagnosis of mediastinal germ cell tumor, mixed type involving seminoma, immature teratoma and embryonal carcinoma, was made by transthoracic needle biopsy.
  • Examination of bone marrow revealed increased atypical large histiocytes (5.6%) with hemophagocytosis, and thus, hemophagocytic syndrome related to germ cell tumor was diagnosed.
  • Chemotherapies for germ cell tumor and hemophagocytic syndrome were performed without any improvement, and he died of diffuse alveolar damage.
  • Autopsy revealed diffuse infiltration of immature histiocytes with hemophagocytosis in the liver, spleen and bone marrow.
  • The atypical histiocytes were positive for CD68 and lysozyme and negative for lymphoid markers, and the diagnosis of true malignant histiocytosis associated with mediastinal germ cell tumor was made.
  • [MeSH-major] Chromosomes, Human, Pair 9. Histiocytic Sarcoma / pathology. Lymphohistiocytosis, Hemophagocytic / pathology. Mediastinal Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Second Primary / pathology. Trisomy
  • [MeSH-minor] Adult. Antigens, CD. Antigens, Differentiation, Myelomonocytic. Biopsy, Needle. Bone Marrow / pathology. Histiocytes / pathology. Humans. Japan. Liver / pathology. Male. Muramidase. Pulmonary Alveoli / pathology. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Chromosome 9, Trisomy.
  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809892.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


11. Hellerbrand C, Bataille F, Schlegel J, Hartmann A, Mühlbauer M, Schölmerich J, Büttner R, Hofstädter F, Bosserhoff AK: In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers. Liver Int; 2005 Apr;25(2):357-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed liver tissue of patients with chronic hepatitis C (HepC) infection and hepatocellular carcinoma (HCC) as well as a human multi-tissue array, primary human hepatocytes and the hepatoma cell-lines HepG2, Hep3B and PLC by immunohistochemical staining and quantitative RT-PCR.
  • RESULTS: Hepatocytes were confirmed as the exclusive cellular source of MIA2 expression, with a granular, cytoplasmatic staining pattern without enhancement at the cell membrane.
  • In contrast, only low MIA2 expression levels were detected in most HCC and hepatoma cell lines.
  • Interestingly, both in HCC and liver tissues of patients with HepC we found a correlation of MIA2 and alpha-sma expression.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatitis, Chronic / pathology. Liver Cirrhosis / pathology. Liver Neoplasms / pathology. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Base Sequence. Biomarkers / analysis. Biopsy, Needle. Case-Control Studies. Extracellular Matrix Proteins. Female. Gene Expression Regulation, Neoplastic. Hepatocytes / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Molecular Sequence Data. Prognosis. RNA, Neoplasm / analysis. RNA, Viral / analysis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2005
  • (PMID = 15780062.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Extracellular Matrix Proteins; 0 / MIA protein, human; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / RNA, Viral
  •  go-up   go-down


12. Sha D, He YJ: [Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma]. Ai Zheng; 2006 Feb;25(2):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma].
  • This study was to explore the correlations of VEGF, Flt-1 and KDR expression to clinical features and prognosis of nasopharyngeal carcinoma (NPC) patients.
  • VEGF expression was related to primary tumor site, lymph node metastasis, and clinical stage (P=0.04, P<0.01, P=0.02, respectively); KDR expression was related to primary tumor site (P=0.03); all of them were related to local recurrence and/or distal metastasis (P<0.01, P<0.01, P=0.01, respectively), and poor overall survival (P<0.01, P=0.01, P=0.03, respectively).
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Nasopharyngeal Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Female. Follow-Up Studies. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480593.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


13. Tanioka M, Katsumata N, Sasajima Y, Ikeda S, Kato T, Onda T, Kasamatsu T, Fujiwara Y: Clinical characteristics and outcomes of women with stage IV endometrial cancer. Med Oncol; 2010 Dec;27(4):1371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neither surgery as primary therapy nor optimal cytoreduction was significantly related to overall survival in either the 28 patients in whom stage IV was diagnosed preoperatively or in all 41 patients.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Neoplasm, Residual / surgery
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):4-9 [14751130.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):85-91 [10926785.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):285-91 [17688923.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):56-60 [9345357.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):448-53 [12366661.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):325-33 [17532033.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):10-4 [14751131.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):133-8 [15385122.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):345-52 [15099944.001]
  • (PMID = 20024630.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Zhu H, Chen XP, Zhang WG, Luo SF, Zhang BX: Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol; 2005 Jul 7;11(25):3855-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma.
  • AIM: To investigate expression and significance of inhibitor of apoptosis protein survivin in hepatocellular carcinoma (HCC).
  • METHODS: The expression of survivin and vascular endothelial growth factor (VEGF) was investigated in 38 cases of HCC tissues and 38 liver cirrhosis tissues by immunohistochemistry and Western blot.
  • RESULTS: Survivin protein was detected in 23 (60.5%) of 38 HCCs and 3 (7.9%) of 38 liver cirrhosis tissues.
  • In liver cirrhosis tissues, the expression of VEGF was as follows: 24 cases were negative, 10 cases were weak positive and 4 cases were strong positive.
  • The expression of survivin in the primary lesion is very useful as an indicator for metastasis and prognosis of HCC.
  • [MeSH-major] Apoptosis. Carcinoma, Hepatocellular / physiopathology. Liver Neoplasms / physiopathology. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991282.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC4504885
  •  go-up   go-down


15. Ding T, Xu J, Wang F, Shi M, Zhang Y, Li SP, Zheng L: High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol; 2009 Mar;40(3):381-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection.
  • This study attempted to investigate the prognostic values of tumor-infiltrating macrophages in patients with hepatocellular carcinoma after resection, paying particular attention to their tissue microlocalization.
  • The CD68(+) macrophages were assessed by immunohistochemistry in tissues from 137 patients with hepatocellular carcinoma.
  • Our results demonstrate that high macrophage infiltration predicts poor prognosis in patients with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Macrophages / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Cell Count. Cell Line, Tumor. Cell Movement. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992916.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


16. Cui Y, Bi M, Su T, Liu H, Lu SH: Molecular cloning and characterization of a novel esophageal cancer related gene. Int J Oncol; 2010 Dec;37(6):1521-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulse-chase experiments showed that ECRG2 protein was detected in both cell lysates and culture medium, indicating that the ECRG2 protein was extracellularly secreted after the post-translational cleavage.
  • Northern blot analysis revealed the presence of the major band corresponding to a size of 569 kb throughout the fetal skin, thymus, esophagus, brain, lung, heart, stomach, liver, spleen, colon, kidney, testis, muscle, cholecyst tissues and adult esophageal mucosa, brain, thyroid tissue and mouth epithelia.
  • However, ECRG2 gene was significantly down-regulated in primary esophageal cancer tissues.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Proteinase Inhibitory Proteins, Secretory / genetics
  • [MeSH-minor] Adult. Amino Acid Sequence. Base Sequence. Chromosome Mapping. Cloning, Molecular. Computational Biology. DNA, Complementary / analysis. DNA, Complementary / isolation & purification. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. Models, Molecular. Molecular Sequence Data. Neoplasm Invasiveness. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042721.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINK7 protein, human
  •  go-up   go-down


17. Moghimi-Dehkordi B, Safaee A, Ghiasi S, Zali MR: Survival in gastric cancer patients: univariate and multivariate analysis. East Afr J Public Health; 2009 Apr;6 Suppl(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Retrospective study of overall patients diagnosed with gastric cancer registered in the cancer registry center of Research Center for Gastroenterology and Liver Disease (RCGLD), Shahid Beheshti University, M.C, Tehran, Iran, between Dec.
  • CONCLUSIONS: According to results, early detection of cancer in lower ages and in primary grades of tumor is important to increase patient's life expectancy.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Signet Ring Cell / mortality. Stomach Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Iran / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084985.001).
  • [ISSN] 0856-8960
  • [Journal-full-title] East African journal of public health
  • [ISO-abbreviation] East Afr J Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tanzania
  •  go-up   go-down


18. Zhong XG, He S, Yin W, Deng JY, Chen B: [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro]. Zhonghua Gan Zang Bing Za Zhi; 2005 Sep;13(9):644-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro].
  • OBJECTIVE: To explore the biological behavior of adult liver stem cells in a co-cultured system of them with hepatocellular carcinoma (HCC) cells without direct contact between the two kinds of cells.
  • METHODS: WB-F344, a kind of rat adult liver stem cell, and rat embryonic fibroblasts (REF) from a primary culture were engineered to express enhanced green fluorescent protein (EGFP) by recombinant adenoviral-mediated methods.
  • After the HCC cells grew to 40%-60% confluence in the culture dish with a 10-mm cell-free area, a similar number of WB-EGFP and REF-EGFP were placed in the blank areas respectively.
  • Their appearance was found not only when WB-EGFP cells were seeded into the cell-free area at the center of the dish, but also when seeded into the blank area at the extreme edge of the plate.
  • CONCLUSIONS: The results mean that adult liver stem cells have a biological behavior of selective tropism toward HCC cells in vitro, and suggest a possibility of using migratory liver stem cells as a delivery vehicle for gene therapy for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / cytology. Liver Neoplasms / pathology. Stem Cells / cytology

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174449.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Granci V, Bibeau F, Kramar A, Boissière-Michot F, Thézénas S, Thirion A, Gongora C, Martineau P, Del Rio M, Ychou M: Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer; 2008 Oct;44(15):2312-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drug resistance is believed to cause treatment failure in patients with metastatic colorectal carcinoma (CRC).
  • Resistance to chemotherapy can involve different processes, including apoptosis, whose extrinsic pathway is regulated by expression of death-inducing TRAIL-R1 and -R2 and inhibitory TRAIL-R3 and -R4 cell surface receptors.
  • We analysed TRAIL-R 1, -2, -3 and -4 expression by immuno-histochemistry in CRC, using tissue micro arrays, and found that concomitant low/medium TRAIL-R1 and high TRAIL-R3 expression in primary CRC is significantly associated with a poor response to 5-FU-based first-line chemotherapy and with shorter progression-free survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Disease Progression. Disease-Free Survival. Female. Fluorouracil / therapeutic use. GPI-Linked Proteins. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Proteins / metabolism. Prognosis. Treatment Outcome. Tumor Necrosis Factor Decoy Receptors / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755584.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10C protein, human; 0 / Tumor Necrosis Factor Decoy Receptors; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD: Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer; 2008 Jun;60(3):374-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
  • OBJECTIVE: To evaluate the progression-free rate (PFR) at 3 months (13+/-1 weeks), antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h continuous i.v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC).
  • PFR (primary efficacy endpoint) and objective response rate (secondary efficacy endpoint) were evaluated according to RECIST, while the toxic profile of plitidepsin was assessed using the NCI-CTC, version 2.0.
  • One patient was responder for the primary (PFR at 13+/-1 weeks) and secondary efficacy endpoint (stable disease according to RECIST).
  • Other two patients were non-responders for the primary efficacy endpoint, but had stable disease (not confirmed at weeks 13+/-1 due to previous withdrawal due to adverse events).
  • The most common side effects were anemia, and asymptomatic and non-cumulative increases of gamma-glutamyltransferase (GGT) and liver transaminase levels.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Depsipeptides / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Urochordata
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Animals. Disease Progression. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Transaminases / blood. gamma-Glutamyltransferase / blood


21. Shengbing Z, Feng LJ, Bin W, Lingyun G, Aimin H: Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma. Anat Rec (Hoboken); 2009 Aug;292(8):1128-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma.
  • KiSS-1 has been identified as a putative metastasis-suppressor gene in human melanomas and breast cancer cell lines.
  • The expression of KiSS-1 protein in HCC and intrahepatic metastasis lesions was significantly lower (P < 0.01) when compared with non-tumor liver tissue and normal liver tissue.
  • Loss of KiSS-1 in intrahepatic metastasis versus primary carcinomas was statistically significant (P<0.01).
  • We conclude that loss of KiSS-1 during HCC metastasis, along with a concomitant upregulation of MMP-9 suggests a possible mechanism for cell motility and invasion during HCC metastasis, with KiSS-1 emerging as a possible therapeutic target during HCC metastasis.
  • [MeSH-major] Biomarkers, Tumor / physiology. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Adult. Aged. Disease Progression. Down-Regulation. Female. Gene Expression. Humans. Kisspeptins. Male. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19645016.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / Tumor Suppressor Proteins; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


22. Dong-Dong L: Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro. Hepatogastroenterology; 2005 Jul-Aug;52(64):1186-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro.
  • BACKGROUND/AIMS: We screened a novel gene MLC1 in human liver cancer tissue by differential display, and its cDNA full-length is 1600bp.
  • The purpose of this study is to find expression of MLC1 gene in human liver cancer tissue and the affect to SMMC7721 cell tumorigenesis in vivo and vitro.
  • METHODOLOGY: 250 cases of primary HCC tissue samples were studied for MLC1 mRNA and protein expression using RT-PCR, western blot, immunohistochemistry, MLC1 stable transfection into SMMC771, and SMMC7721 cells growth curve was analyzed by MTT method and SMMC7721 cells tumorigenesis in vivo.
  • CONCLUSIONS: MLC1 gene showed up-regulation expression at both the mRNA and protein levels in HCC tissues and that MLC1 plays an important role in the growth of hepatoma cell SMMC7721 in vitro and vivo.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / etiology. Liver Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Animals. Cell Culture Techniques. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged. RNA, Messenger / metabolism. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001658.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MLC1 protein, human; 0 / Membrane Proteins; 0 / Mlc1 protein, mouse; 0 / RNA, Messenger
  •  go-up   go-down


23. Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Cheng GY, Wong RS, Lai PP, Leung TW, Tang JC, Chan AS: Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. Int J Mol Med; 2006 May;17(5):945-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines.
  • The cytotoxic activity of this analogue was screened on both Hep3B hepatocellular carcinoma and SK-Hep-1 liver adenocarcinoma cell lines by [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay.
  • Morphological changes of hepatoma cell lines were recorded under an inverted microscope.
  • The possible tolerance of these analogues was further investigated using non-malignant haematological bone marrow primary culture.
  • CAN 032 showed a significant cytotoxic response on both hepatoma cell lines in which the potencies were comparable to that of cantharidin.
  • Phase contrast microscopy demonstrated that cell shrinkage, rounding, loss of adherent property and loss of colony-formation ability were induced.
  • [MeSH-minor] Adult. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / physiopathology. Cell Cycle / drug effects. Cell Line, Tumor. Cell Size / drug effects. DNA Fragmentation / drug effects. Dose-Response Relationship, Drug. Female. Humans. Male. Microscopy, Phase-Contrast. Molecular Structure. Thiazoles / chemical synthesis. Thiazoles / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CANTHARIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596285.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CAN 032; 0 / Thiazoles; IGL471WQ8P / Cantharidin
  •  go-up   go-down


24. Dokmak S, Cabral C, Couvelard A, Aussilhou B, Belghiti J, Sauvanet A: Pancreatic metastasis from nephroblastoma: an unusual entity. JOP; 2009;10(4):396-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Pancreatic metastasis from renal cell carcinoma is a well-known entity.
  • A metastatic nephroblastoma mainly affects the lung and the liver.
  • CASE REPORT: We report an extremely rare case of pancreatic metastases in a 20-year-old man who had a right nephroblastoma resected at 9 years of age and liver metastases treated by right hepatectomy at 18 years of age.
  • Imaging studies revealed no other localization except a 1.5 cm liver nodule.
  • The patient underwent pancreaticoduodenectomy and limited liver resection with an uneventful postoperative course.
  • Pathological examination confirmed pancreatic and liver metastases from a nephroblastoma composed of blastematous cells mixed with embryonic tubular structures without lymph node metastases.
  • After resection, the patient received adjuvant high dose chemotherapy with autologous hematopoietic stem-cell support.
  • After a 21-month follow-up, the patient was in good general condition but had liver recurrence without intra-pancreatic recurrence.
  • A nephroblastoma, like clear cell renal carcinoma, can be considered a possible etiology of pancreatic metastasis from a primary renal tumor.
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy / methods. Humans. Male. Pancreaticoduodenectomy / methods. Treatment Outcome. Young Adult


25. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis


26. Ceafalan L, Vidulescu C, Radu E, Regalia T, Popescu I, Pana M, Serghei L, Voiculescu B, Popescu LM: [Expression of stem cell markers on fetal and tumoral human liver cells in primary culture]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):96-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of stem cell markers on fetal and tumoral human liver cells in primary culture].
  • We have identified populations expressing these markers in both fetal and tumoral human liver by flow cytometry, using monoclonal antibodies against CD90, CD117, CD34, and HLA-DR.
  • In tumoral liver CD117+/CD90+ cells were found in decreasing number from the neoplastic (2.48 +/- 0.67) and peritumoral region (0.88 +/- 0.12) to the area of para-tumoral (normal) parenchyma (0.13 +/- 0.04).
  • Using the same markers on fetal liver cells we have also identified small populations of CD117+/CD90+ cells (0.28 +/- 0.07%) and CD117+/CD34+ cells (1.13 +/- 0.24%), presumably resident stem cells or hematopoietic stem cells.
  • Immunomagnetic negative separation was then performed on fetal liver cells using monoclonal antibodies against specific markers of hematopoietic lineages such as CD3, 14, 16, 19, 22, and CD56 to eliminate this population.
  • Isolation using appropriate markers and initiation of primary cultures is a first step to the therapeutic use of fetal stem cells and for the study of adult liver stem cells involvement in carcinogenesis.
  • [MeSH-major] Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / immunology. Fetus. Hepatocytes / immunology. Liver Neoplasms / immunology. Stem Cells
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antigens, Thy-1 / analysis. Flow Cytometry. HLA-DR Antigens / analysis. Humans. Immunomagnetic Separation. Microscopy, Fluorescence. Proto-Oncogene Proteins c-kit / analysis. Stem Cell Transplantation / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607835.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Thy-1; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


27. Liu ZZ, Huang WY, Lin JS, Li XS, Lan X, Cai XK, Liang KH, Zhou HJ: Cell survival curve for primary hepatic carcinoma cells and relationship between SF(2) of hepatic carcinoma cells and radiosensitivity. World J Gastroenterol; 2005 Nov 28;11(44):7040-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell survival curve for primary hepatic carcinoma cells and relationship between SF(2) of hepatic carcinoma cells and radiosensitivity.
  • AIM: To establish the cell survival curve for primary hepatic carcinoma cells and to study the relationship between SF(2) of primary hepatic carcinoma cells and radiosensitivity.
  • METHODS: Hepatic carcinoma cells were cultured in vitro using 39 samples of hepatic carcinoma at stages II-IV.
  • After these cells were radiated with different dosages, the cell survival ratio and SF(2) were calculated by clonogenic assay and SF(2) model respectively.
  • After X-ray radiation of the fifth generation cells with 0, 2, 4, 6, 8 Gy, the cell survival rate was 41%, 36.5%, 31.0%, 26.8%, and 19%, respectively.
  • There was a negative correlation between cell survival and irradiation dosage (r = -0.973, P<0.05).
  • SF(2) ranged 0.28-0.78 and correlated with the clinical stage and pathological grade of hepatic carcinoma (P<0.05).
  • CONCLUSION: SF(2) correlates with the clinical stage and pathological grade of hepatic carcinoma and is a marker for predicting the radiosensitivity of hepatic carcinomas.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiotherapy. Cell Survival. Liver Neoplasms / pathology. Liver Neoplasms / radiotherapy. Radiation Tolerance
  • [MeSH-minor] Adult. Aged. Animals. Cell Culture Techniques. Dose-Response Relationship, Radiation. Humans. Middle Aged. Neoplasm Staging. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437614.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4717052
  •  go-up   go-down


28. Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, Stief CG, Jauch KW, Bruns CJ: Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol; 2010 Aug;28(4):543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis.
  • The value of surgical resection of renal cell carcinoma (RCC) liver metastases still remains unclear.
  • OBJECTIVE: Of our study was to evaluate the efficacy of liver resection by comparing patients who could have undergone metastasectomy due to limited disease, but refused surgery.
  • MATERIALS AND METHODS: Eighty-eight patients were identified with liver metastases and indication of surgery between 1995 and 2006.
  • In 68 patients, liver resection was performed, 20 patients denied surgery and served as comparison group.
  • Median amount of liver metastases was 2 (range 1-30).
  • Low-grade primary RCC had a MS of 155 (95% CI 123-187) months compared to 29 (95% CI 8-50) months without resection (P = 0.0036).
  • CONCLUSIONS: Liver metastasectomy is an independent valuable tool in the treatment of metastatic RCC and significantly prolongs patient's survival, even if further systemic treatment is necessary.
  • With the evidence given, patients may benefit from liver metastasis resection if technically feasible.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Liver / surgery. Liver Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Databases, Factual. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Young Adult


29. Luo DL, Liu YH, Zhuang HG, Luo XL: [Tumors showing perivascular epithelioid cell differentiation: a clinicopathologic study of 39 cases]. Zhonghua Yi Xue Za Zhi; 2007 Nov 6;87(41):2909-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumors showing perivascular epithelioid cell differentiation: a clinicopathologic study of 39 cases].
  • OBJECTIVE: To investigate the clinicopathologic features of tumors showing perivascular epithelioid cell differentiation (PEComas).
  • METHODS: The clinicopathologic data of 39 cases pf angiomyolipoma (AML), 17 males and 22 females, with the primary focus in the kidney on 30 cases, in the liver in 4 cases, in the lung, uterus and broad ligament, abdominal wall, retroperitoneum, and nasal cavity in 1 case respectively, were analyzed.
  • RESULTS: Pathological examination showed branched capillaries or arterioles, often thick-walled similar to those in the renal cell carcinoma, and the cancerous cells consisting of the mixture of epithelial cells and spindle cells.
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / analysis. Cell Differentiation. Desmin / analysis. Female. Humans. Immunohistochemistry. Keratins / analysis. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Middle Aged. Nose Neoplasms / metabolism. Nose Neoplasms / pathology. Proto-Oncogene Proteins c-kit / analysis. Retrospective Studies. S100 Proteins / analysis. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261305.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Desmin; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


30. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, Tan YS, He J: Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer; 2009;9:176
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival.
  • This study was conducted to analyze the association of CXCR4 expression with hepatocellular carcinoma (HCC) bone metastasis and patient survival.
  • CXCR4 overexpression in primary tumors (n = 91) decreased overall median survival (18.0 months vs. 36.0 months, P <0.001).
  • CONCLUSION: CXCR4 expression in primary HCCs may be an independent risk factor for bone metastasis and may be associated with poor clinical outcome.
  • [MeSH-major] Bone Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Receptors, CXCR4 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Immunohistochemistry. Male. Microarray Analysis / methods. Middle Aged. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):833-5 [11556308.001]
  • [Cites] Cell Mol Immunol. 2008 Oct;5(5):373-8 [18954561.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] J Pediatr Surg. 2004 Oct;39(10):1506-11 [15486895.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):318-29 [15647826.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4658-65 [16000558.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):879-94 [15888687.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):93-5 [16098461.001]
  • [Cites] Cancer Lett. 2005 Oct 18;228(1-2):203-9 [15975706.001]
  • [Cites] Braz J Med Biol Res. 2005 Oct;38(10):1449-54 [16172737.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8273-80 [16322285.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1840-7 [16368946.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1761-7 [16269611.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jul 21;346(1):252-8 [16756955.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):210-7 [16819541.001]
  • [Cites] Neoplasia. 2007 Jan;9(1):36-46 [17325742.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):902-9 [17504862.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3):570-8; discussion 578-9 [17881971.001]
  • [Cites] Clin Exp Metastasis. 2008;25(1):1-10 [17768666.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):420-32 [17906299.001]
  • [Cites] Mol Cancer Res. 2008 Mar;6(3):446-57 [18337451.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4747-57 [11591806.001]
  • (PMID = 19508713.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Receptors, CXCR4
  • [Other-IDs] NLM/ PMC2704220
  •  go-up   go-down


31. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol; 2009 Jun 20;27(18):3027-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
  • PURPOSE: To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response.
  • The primary end point was progression-free survival (PFS).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers / blood. Carcinoma, Hepatocellular / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemokine CXCL12 / blood. Female. Humans. Interleukin-6 / blood. Magnetic Resonance Imaging. Male. Middle Aged. Stem Cells / cytology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Oncologist. 2006 Jul-Aug;11(7):790-800 [16880238.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Apr;19(3):204-8 [17359908.001]
  • [Cites] Nat Protoc. 2007;2(4):805-10 [17446880.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Nat Biotechnol. 2007 Aug;25(8):911-20 [17664940.001]
  • [Cites] Trends Mol Med. 2008 Mar;14(3):109-19 [18261959.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4672-8 [18824714.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gut. 2001 Jan;48(1):87-96 [11115828.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Nat Med. 2003 Jun;9(6):789-95 [12740570.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3955-64 [14517187.001]
  • [Cites] Br J Radiol. 2003;76 Spec No 1:S83-6 [15456717.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3004-9 [8674055.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):3-23 [15757802.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3):G571-8 [15860640.001]
  • [Cites] Oncology. 2005;69(5):363-71 [16319507.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [CommentIn] J Clin Oncol. 2009 Dec 10;27(35):e248-50; author reply e251-2 [19901099.001]
  • (PMID = 19470923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR001066; United States / NCI NIH HHS / CA / P01 CA080124; United States / NCI NIH HHS / CA / P01 CA80124; United States / NCI NIH HHS / CA / K23 CA139005; United States / NCRR NIH HHS / RR / M01-RR-01066; United States / NCI NIH HHS / CA / R01 CA115767
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Chemokine CXCL12; 0 / Indoles; 0 / Interleukin-6; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC2702235
  •  go-up   go-down


32. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol; 2005 Aug 14;11(30):4661-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue.
  • AIM: To investigate the relation between MUC1 expression, distribution, and prognosis in hepatocellular and cholangiocarcinoma (HCC and CC) and cirrhotic liver tissues, and their significance in HCC and CC diagnosis.
  • METHODS: Expression and distribution of MUC1 were examined by immunohistochemical assay with anti-MUC1 mAb in 59 samples of HCC and 37 samples of CC, 20 samples of cirrhotic liver tissues, and 10 samples of normal liver tissues, seeking possible associations between MUC1 positive expression, distribution in HCC and CC (primary liver cancer, PLC) cases and the studied clinical data.
  • Only 4 in the 20 cirrhotic liver tissues were found to be weak positive, while no expression of MUC1 was detected in normal liver tissues.
  • Apparently, the high expression rate of MUC1 in PLC tissues was statistically significant in comparison to that in cirrhotic and normal liver tissues.
  • The expressed MUC1 protein, stained in dark brownish or brownish-yellow particles, chiefly localized on the cancer cell membranes or in cytoplasm.
  • In the 68 strong positive samples, 40 were detected on cell membrane and the other 28 were in cytoplasm.
  • In addition, follow-up studies of those PLC cases demonstrated that MUC1 expression on cell membrane or in cytoplasm was closely associated with PLC prognosis.
  • CONCLUSION: Expression and localization of MUC1 proteins in primary liver carcinomas (PLCs) may act as prognostic markers, and MUC1 molecules might be helpful in differential diagnosis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cholangiocarcinoma / metabolism. Liver Neoplasms / metabolism. Mucin-1 / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Liver Cirrhosis / metabolism. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094706.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucin-1
  • [Other-IDs] NLM/ PMC4615407
  •  go-up   go-down


33. Zoller H, McFarlane I, Theurl I, Stadlmann S, Nemeth E, Oxley D, Ganz T, Halsall DJ, Cox TM, Vogel W: Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology; 2005 Aug;42(2):466-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease.
  • In the index case, the disorder is characterized by abundant deposition of hemosiderin in all tissues investigated (mesenteric lymph node, liver, gastric and duodenal mucosa, and also in squamous cell carcinoma of the lung).
  • Despite a significant burden of iron, no features of chronic liver disease were found in affected members of the family, including individuals aged up to 80 years.
  • In conclusion, the systemic iron burden in ferroportin disease is not a sufficient cause for chronic liver disease.
  • In patients with most, but not all, ferroportin mutations, retention of iron in macrophages of the liver and other organs may protect against damage to parenchymal cells.
  • [MeSH-minor] Adolescent. Adult. Aged. Ferritins / blood. Hepcidins. Humans. Liver / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Iron Overload.
  • MedlinePlus Health Information. consumer health - Hemochromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986403.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Cation Transport Proteins; 0 / HAMP protein, human; 0 / Hepcidins; 0 / Protein Precursors; 0 / metal transporting protein 1; 9007-73-2 / Ferritins
  •  go-up   go-down


34. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC: Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer; 2007 Mar;43(4):736-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
  • Tumour-associated trypsin inhibitor (TATI) overexpresses in various tumours, but its clinicopathological significance in hepatocellular carcinoma (HCC) is unclear.
  • By RT-PCR in the linear range, TATI was found to be overexpressed in 176 of 258 unifocal primary HCCs (68%).
  • Ectopic expression of TATI led to enhanced anchorage-independent tumour cell growth in vitro.
  • We conclude that TATI overexpression contributes to cell growth advantage, enhances the metastatic potential of tumours and leads to advanced HCC with PV invasion.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neoplasm Proteins / metabolism. Portal Vein. Trypsin Inhibitor, Kazal Pancreatic / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. HeLa Cells / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Osteopontin / metabolism. Prognosis. Survival Analysis. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267202.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 106441-73-0 / Osteopontin; 50936-63-5 / Trypsin Inhibitor, Kazal Pancreatic
  •  go-up   go-down


35. Lao XM, Zhang YQ, Jin X, Lin XJ, Guo RP, Li GH, Li JQ: Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases. Hepatogastroenterology; 2006 Jan-Feb;53(67):128-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases.
  • BACKGROUND/AIMS: Primary clear cell carcinoma of the liver (PCCCL) is a subgroup of hepatocellular carcinoma.
  • The differentiation degree ranged from grade 1 to 3, liver cirrhosis or/and chronic hepatitis was present in paratumorous tissues.
  • The clinical characteristics of the PCCCL are similar to those of conventional hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506391.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


36. Brouwer J, Senft A, de Bree R, Comans EF, Golding RP, Castelijns JA, Hoekstra OS, Leemans CR: Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol; 2006 Mar;42(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The detection of distant metastases and second primary tumours at the time of initial evaluation changes the prognosis and influences the selection of treatment modality in patients with HNSCC.
  • In this observational cohort study we prospectively compared the yield of whole body (18)FDG-PET and chest CT to detect distant metastases and synchronous primary tumours.
  • Four patients were diagnosed with distant metastases or second primary tumours: CT as well as (18)FDG-PET identified one patient with lung metastases and another with primary lung cancer.
  • In addition, (18)FDG-PET detected second primary tumours in two patients (hepatocellular carcinoma and abdominal adenocarcinoma).
  • However increased uptake sites at (18)FDG-PET in lung, liver and pelvis in five patients were not confirmed by other imaging modalities.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Fluorodeoxyglucose F18. Head and Neck Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / radionuclide imaging. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266820.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Rubie C, Frick VO, Pfeil S, Wagner M, Kollmar O, Kopp B, Graber S, Rau BM, Schilling MK: Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol; 2007 Oct 7;13(37):4996-5002
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the expression profile of IL-8 in inflammatory and malignant colorectal diseases to evaluate its potential role in the regulation of colorectal cancer (CRC) and the development of colorectal liver metastases (CRLM).
  • METHODS: IL-8 expression was assessed by quantitative real-time PCR (Q-RT-PCR) and the enzyme-linked immunosorbent assay (ELISA) in resected specimens from patients with ulcerative colitis (UC, n = 6) colorectal adenomas (CRA, n = 8), different stages of colorectal cancer (n = 48) as well as synchronous and metachronous CRLM along with their corresponding primary colorectal tumors (n = 16).
  • Most interestingly, IL-8 up-regulation was most enhanced in synchronous and metachronous CRLM, if compared with the corresponding primary CRC tissues.
  • CONCLUSION: Our results strongly suggest an association between IL-8 expression, induction and progression of colorectal carcinoma and the development of colorectal liver metastases.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854143.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-8
  • [Other-IDs] NLM/ PMC4434624
  •  go-up   go-down


38. Fan ZH, Chen MH, Dai Y, Wang YB, Yan K, Wu W, Yang W, Yin SS: Evaluation of primary malignancies of the liver using contrast-enhanced sonography: correlation with pathology. AJR Am J Roentgenol; 2006 Jun;186(6):1512-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of primary malignancies of the liver using contrast-enhanced sonography: correlation with pathology.
  • OBJECTIVE: Our purpose was to investigate the correlation of contrast-enhanced sonographic patterns with the histopathology of primary malignancies of the liver.
  • RESULTS: All 65 moderately to poorly differentiated hepatocellular carcinomas (HCCs) enhanced in the arterial phase, and 96.9% (63 lesions) of them quickly washed out in the portal venous phase.
  • Seventy-five percent of the clear cell carcinomas (12/16) enhanced in the arterial phase, 25% (4/16) did not enhance until the portal venous phase, and 31.3% (5/16) of the clear cell carcinomas washed out slowly during the late phase.
  • The enhancement and washout times of clear cell carcinomas were significantly different than those of moderately to poorly differentiated HCCs (p < 0.05).
  • CONCLUSION: Our study showed that the enhancement manifestations of primary malignancies of the liver are related to pathologic types and grades.
  • Contrast-enhanced sonograms may provide the histopathologic information for malignant tumors of the liver.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / ultrasonography. Contrast Media. Liver Neoplasms / pathology. Liver Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714638.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


39. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY: Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med; 2005 Aug 31;37(4):276-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the RUNX3 gene in hepatocellular carcinoma.
  • To elucidate the potential etiological role of the RUNX3 gene in the development of hepatocellular carcinoma (HCC), we have analyzed the methylation status of 5' CpG island of the RUNX3 gene in a series of 73 HCC tissues and 11 liver cell lines.
  • Expectedly, promoter methylation of RUNX3 gene was found in 2 (2.7%) of 73 corresponding normal liver, whereas 30 (41.1%) of 73 HCCs and 4 (40%) of 10 liver cancer cell lines showed hypermethylation of the gene, respectively.
  • There was no significant difference between promoter hypermethylaion and clinicopathologic parameters of primary HCC samples, including histologic grade, microvascular invasion, and clinical stage.
  • Interestingly, demethylating agent 5-aza-2-deoxycytidine induced reactivation and more potent expression of RUNX3 gene in HCC cell lines.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Neoplasm / metabolism. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155404.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


40. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol; 2010 Nov 20;28(33):4953-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
  • We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC).
  • The primary outcome was objective response rate (ORR).
  • Grade 3 or higher liver function abnormalities were observed in nine patients (11.8%).
  • [MeSH-major] Benzoquinones / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Rearrangement. Humans. Male. Middle Aged. Mutation. Prospective Studies. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20940188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 4GY0AVT3L4 / tanespimycin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC4676802
  •  go-up   go-down


41. Jing Z, Nan KJ, Hu ML: Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol; 2005 Apr 7;11(13):1910-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma.
  • AIM: To investigate the expression of cell apoptosis, proliferation and the related regulators p27, p53 in hepatocellular carcinoma (HCC).
  • METHODS: The expression of p27, p53, proliferating cell nuclear antigen (PCNA) and apoptosis in 47 HCC specimens and 42 surrounding non-cancerous tissues were detected by the immunohistochemistry and terminal deoxy-nucleotidyl transferase-mediated nick end labeling (TUNEL) technique.
  • (1) The average proliferating index and apoptotic index in HCC were significantly higher than that in adjacent liver tissues.
  • (2) The level of p27 in the cytoplasmic fraction was higher in non-tumoral liver tissues and was associated with clinical stage;.
  • The combined examination of p27, and p53 expression allows reliable estimation of prognosis for patients with primary hepatic carcinoma.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Hepatocellular / metabolism. Cell Cycle Proteins / metabolism. Liver Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Division / physiology. Cyclin-Dependent Kinase Inhibitor p27. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800979.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC4305710
  •  go-up   go-down


42. Mihai R, Stevens J, McKinney C, Ibrahim NB: Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol; 2006 Jun;32(5):511-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: This study investigates whether the calcium-sensing receptor (CaR) is commonly expressed in primary breast cancers.
  • The CaR controls secretion of PTHrP in several breast cancer cell lines and PTHrP is known to stimulate osteolysis during metastatic bone resorption.
  • METHODS: With Ethical Committee approval, immunohistochemistry was performed using a commercially available antiCaR antibody (AffinityBioReagents, Cambridge, UK) on archived histological sections of primary tumours from patients who died with advanced breast cancer.
  • Of the patients with negative bone scans, 23 had liver or lung metastases.
  • CONCLUSIONS: CaR expression is common in a selected group of patients with advanced primary breast cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Cause of Death. Female. Forecasting. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Middle Aged. Parathyroid Hormone-Related Protein / secretion. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564154.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Parathyroid Hormone-Related Protein; 0 / Receptors, Calcium-Sensing; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


43. Chan KY, Lai PB, Squire JA, Beheshti B, Wong NL, Sy SM, Wong N: Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod Pathol; 2006 Dec;19(12):1546-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.
  • Molecular characterizations of hepatocellular carcinoma have indicated frequent allelic losses on chromosomes 4q, 8p, 16q and 17p, where the minimal deleted regions have been further defined on 4q12-q23, 4q31-q35, 8p21-p22, 16q12.1-q23.1 and 17p13.
  • Despite these regions are now well-recognized in early liver carcinogenesis, few underlying candidate genes have been identified.
  • In an effort to define affected genes within common deleted loci of hepatocellular carcinoma, we conducted transcriptional mapping by high-resolution cDNA microarray analysis.
  • In 20 hepatocellular carcinoma cell lines and 20 primary tumors studied, consistent downregulations of novel transcripts were highlighted throughout the entire genome and within sites of frequent losses.
  • In primary hepatocellular carcinoma examined, a significant repression of MT1G by more than 100-fold was indicated in 63% of tumors compared to the adjacent nonmalignant liver (P = 0.0001).
  • In summary, transcriptional mapping by microarray indicated a number of previously undescribed downregulated genes in hepatocellular carcinoma, and highlighted potential candidates within common deleted regions.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Deletion. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Down-Regulation. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis


44. Aderca I, Moser CD, Veerasamy M, Bani-Hani AH, Bonilla-Guerrero R, Ahmed K, Shire A, Cazanave SC, Montoya DP, Mettler TA, Burgart LJ, Nagorney DM, Thibodeau SN, Cunningham JM, Lai JP, Roberts LR: The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol; 2008 Sep;49(3):373-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the function of WWOX in human hepatocellular carcinoma (HCC) and the effect of JNK inhibition on WWOX-mediated apoptosis.
  • WWOX mRNA in HCC cell lines and primary HCCs was measured by real-time RT-PCR.
  • Of 11 HCC cell lines, 2 had low, 7 intermediate, and 2 had high WWOX mRNA.
  • Of 51 primary tumors, 23 had low WWOX mRNA.
  • CONCLUSIONS: WWOX induces apoptosis and inhibits human HCC cell growth through a mechanism enhanced by JNK inhibition.

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2005;5:64 [15982416.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5769-77 [16115915.001]
  • [Cites] J Huazhong Univ Sci Technolog Med Sci. 2005;25(2):162-5 [16116962.001]
  • [Cites] Oncogene. 2005 Sep 29;24(43):6590-6 [16007179.001]
  • [Cites] Mol Carcinog. 2005 Nov;44(3):174-82 [16187332.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15611-6 [16223882.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10514-23 [16288044.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1154-8 [16152610.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):43100-8 [16219768.001]
  • [Cites] Surg Today. 2006;36(1):1-5 [16378185.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):37-47 [16242840.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R998-1004 [16280054.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6477-81 [16818616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11417-22 [11572989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6 [11717429.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8068-73 [11719429.001]
  • [Cites] Int J Mol Med. 2002 Jan;9(1):19-24 [11744990.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1832-40 [11896615.001]
  • [Cites] Oncology. 2002;62(2):141-8 [11914600.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2258-60 [11956080.001]
  • [Cites] Hepatology. 2002 May;35(5):1153-63 [11981765.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jun;34(2):154-67 [11979549.001]
  • [Cites] Mol Pharmacol. 2003 Feb;63(2):401-8 [12527812.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):878-81 [12591741.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9195-202 [12514174.001]
  • [Cites] Hepatology. 2003 Apr;37(4):824-32 [12668975.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Sep;38(1):40-52 [12874785.001]
  • [Cites] Cytogenet Genome Res. 2003;100(1-4):101-10 [14526170.001]
  • [Cites] Mol Cancer Res. 2003 Nov;1(13):940-7 [14638866.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8629-33 [14695174.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):231-48 [14699503.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1789-95 [15014033.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1605-14 [15073846.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2459-65 [15073125.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):85-96 [15101042.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3487-94 [15007382.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3053-8 [15131042.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):653-9 [15060557.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1049-53 [10706123.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1690-7 [10749141.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):165-78 [16831600.001]
  • [Cites] J Mol Histol. 2006 May;37(3-4):115-25 [16941225.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):24-31 [17019711.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):268-74 [17200365.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):884-91 [17289881.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3949-54 [17360458.001]
  • [Cites] Gut. 2007 Jul;56(7):982-90 [17185352.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Thyroid. 2007 Nov;17(11):1055-9 [18047428.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):419-27 [18223217.001]
  • [Cites] Genes Chromosomes Cancer. 2008 May;47(5):437-47 [18273838.001]
  • [Cites] Hepatology. 2008 Apr;47(4):1211-22 [18318435.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):251-9 [18365142.001]
  • [Cites] Oral Oncol. 2008 Aug;44(8):753-8 [18061530.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2140-5 [10786676.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1651-63 [10861292.001]
  • [Cites] Genomics. 2000 Oct 1;69(1):37-46 [11013073.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):245-53 [11170281.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):148-68 [11237531.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3361-70 [11058590.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5232-8 [11526514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10250-5 [11517343.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Jun;284(6):G875-9 [12736142.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):753-9 [15266310.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] Cancer Lett. 1991 May 1;57(2):131-5 [1851053.001]
  • [Cites] Jpn J Cancer Res. 1991 Nov;82(11):1263-70 [1721615.001]
  • [Cites] Int J Cancer. 1992 Jul 30;51(6):862-8 [1322376.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10351-5 [9294214.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):714-23 [15580310.001]
  • [Cites] Neuroscience. 2005;130(2):397-407 [15664696.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1625-33 [15674328.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):130-8 [15798093.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1681-9 [15870886.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):471-8 [15998374.001]
  • (PMID = 18620777.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082862-01; United States / NCI NIH HHS / CA / K08 CA082862-02; United States / NCI NIH HHS / CA / CA100882; United States / NCI NIH HHS / CA / K08 CA082862-04; United States / NCI NIH HHS / CA / K08 CA082862-01; United States / NCI NIH HHS / CA / R01 CA100882; United States / NCI NIH HHS / CA / R01 CA100882-01A1; United States / NCI NIH HHS / CA / K08 CA082862-05; United States / NCI NIH HHS / CA / CA082862-05; United States / NCI NIH HHS / CA / CA082862-02; United States / NCI NIH HHS / CA / K08 CA082862-03; United States / NCI NIH HHS / CA / CA082862-04; United States / NCI NIH HHS / CA / CA82862; United States / NCI NIH HHS / CA / K08 CA082862; United States / NCI NIH HHS / CA / CA082862-03; United States / NCI NIH HHS / CA / R56 CA100882
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; EC 1.- / Oxidoreductases; EC 1.1.1.- / WWOX protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 8; H88EPA0A3N / Staurosporine
  • [Other-IDs] NLM/ NIHMS59493; NLM/ PMC2574998
  •  go-up   go-down


45. Guo WX, Man XB, Yuan HX, Shi J, Xue J, Wu MC, Cheng SQ: [Proteomic analysis on portal vein tumor thrombus-associated proteins for hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi; 2007 Aug 14;87(30):2094-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Proteomic analysis on portal vein tumor thrombus-associated proteins for hepatocellular carcinoma].
  • METHODS: proteins extracted from five pairs of matched primary tumor/tumor thrombus samples in the same patient were separated by two-dimensional gel electrophoresis (2-DE).
  • RESULT: There were 20 significant proteins were identified in total, Among the 20 spots, 12 proteins were up-regulated proteins in primary tumor tissue, including Galectin-1, HMGBI, peroxiredoxin 1, Cyclophilin B, PCNA. whereas 8 were up-regulated proteins in tumor thrombus samples, including Annexin V, Triosephosphate Isomerase.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Portal Vein / metabolism. Proteomics / methods
  • [MeSH-minor] Adult. Annexin A5 / analysis. Blotting, Western. Cyclophilins / analysis. Electrophoresis, Gel, Two-Dimensional. Galectin 1 / analysis. HMGB Proteins / analysis. Humans. Male. Mass Spectrometry. Middle Aged. Neoplastic Cells, Circulating / metabolism. Peptidylprolyl Isomerase / analysis. Peroxiredoxins / analysis. Proliferating Cell Nuclear Antigen / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988525.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Galectin 1; 0 / HMGB Proteins; 0 / Proliferating Cell Nuclear Antigen; 137497-17-7 / cyclophilin B; EC 1.11.1.15 / PRDX1 protein, human; EC 1.11.1.15 / Peroxiredoxins; EC 5.2.1.- / Cyclophilins; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


46. Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Suntharalingam M: Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Ann Thorac Surg; 2010 Jan;89(1):200-6; discussion 206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We studied the clinical characteristics and outcomes of patients undergoing pneumonectomy after preoperative concurrent chemoradiation for non-small cell lung cancer.
  • METHODS: Clinical records of patients with non-small cell lung cancer who underwent pneumonectomy at our institution between 1995 and 2005 after preoperative concurrent chemoradiation were reviewed retrospectively.
  • Of the 21 men and 8 women who were treated, 1 had stage IIB (T3N0M0) and the remainder had stage IIIA or IIIB non-small cell lung cancer.
  • Recurrences have been found in 11 patients (38%), including brain metastases (n = 6), bone metastases (n = 4), liver metastases (n = 2), and cervical lymph node metastases (n = 2).
  • One patient had a contralateral new primary lung cancer develop 70 months after undergoing pneumonectomy.
  • The frequency of disease recurrence in the brain underscores the need to evaluate the role of prophylactic cranial radiation in non-small cell lung cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiation Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20103235.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Wang ZP, Liu YT, Yang J: [Classification and regression tree analysis of 154 patients with cancer of unknown primary]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):690-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Classification and regression tree analysis of 154 patients with cancer of unknown primary].
  • OBJECTIVE: To explore the prognostic factors and their impact on survival of patients with cancer of unknown primary (CUP).
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Neoplasms, Unknown Primary / classification
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Regression Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122385.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Boonsakan P, Thangnapakorn O, Tapaneeyakorn J, Kositchaiwat S, Bunyaratvej S: Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation. J Med Assoc Thai; 2007 Mar;90(3):574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation.
  • Combined hepatocellular and cholangiocarcinoma with sarcomatous transformation was first recognized in Ramathibodi Hospital in 2005.
  • This variant of carcinoma has been increasingly reported particularly from Asian countries.
  • The causative factors of hepatocarcinogenesis in Thailand include chronic viral hepatitis B or C, exposures to aflatoxin B1 and nitrosamine(s) and occasionally some certain nodular hepatocellular lesions due to arterial hyperperfusion.
  • It is suggested that the recent change of the Thai peoples' life style to an increased consumption of fast foods containing food preservatives especially nitrate or nitrite, the nitrosamine precursor may allow heavy exposure(s) to the chemical carcinogen(s) i.e. nitrosamine(s) leading to sarcomatous transformation of the carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Humans. Male. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427538.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


49. Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G: Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist; 2010;15(3):285-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
  • The objective of this trial was to demonstrate antitumor activity of continuous SU treatment in patients with hepatocellular carcinoma (HCC).
  • PATIENTS AND METHODS: Key eligibility criteria included unresectable or metastatic HCC, no prior systemic anticancer treatment, measurable disease, and Child-Pugh class A or mild Child-Pugh class B liver dysfunction.
  • The primary endpoint was progression-free survival at 12 weeks (PFS12).
  • CONCLUSION: Continuous SU treatment with 37.5 mg daily is feasible and has moderate activity in patients with advanced HCC and mild to moderately impaired liver dysfunction.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4068-75 [19652072.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7669-74 [11606410.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):290-6 [11668511.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Clin Biochem. 2003 Nov;36(8):585-90 [14636871.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20 [14762851.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):25-35 [16314617.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1753-9 [17470865.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2330-1 [17538098.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):1-14 [18176955.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2992-8 [18565886.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1312-27 [18821591.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):446-52 [19064965.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3027-35 [19470923.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):1959-68 [19282169.001]
  • [Cites] Oncologist. 2009 Jul;14(7):717-25 [19581525.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):794-800 [19586800.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • (PMID = 20203173.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00699374
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC3227954
  •  go-up   go-down


50. Pozharisskiĭ KM, Granov DA, Ten VP, Kubaĭbergenova AG, Leenman EE, Rasskazov AI: [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers]. Vopr Onkol; 2008;54(4):417-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers].
  • The immunohistochemical investigation used 55 primary hepatic tumors (hepatocellular carcinoma (HCC)--32, cholangiocellular carcinoma (CCC)--23).
  • Wide panels of such antibodies as hepatocytic marker (Hep Par--1) CK-8, CK-19, polyclonal CEA, CD10, alpha-fetoprotein, TTF-1 as well as proliferative features of HCC (Ki-67) including regulators of stage-to-stage transition through mitoses of tumor cells (cyclin-D1 and A, genes p53 and RB), unrestricted tumor cell mitosis (telomerases), and intercellular adhesion marker (beta-catenin) were employed for differential diagnosis of neoplasia.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / chemistry. Carcinoma, Hepatocellular / diagnosis. Immunohistochemistry. Liver Neoplasms / chemistry. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Calcium-Binding Proteins / analysis. Carcinoembryonic Antigen / analysis. Cholangiocarcinoma / diagnosis. Cyclin A / analysis. Cyclin D. Cyclins / analysis. DNA-Binding Proteins / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Genes, Retinoblastoma. Genes, p53. Humans. Keratin-19. Keratin-8. Ki-67 Antigen / analysis. Male. Microfilament Proteins / analysis. Middle Aged. Neprilysin / analysis. Prognosis. Risk Factors. Survival Analysis. alpha-Fetoproteins / analysis. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942395.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Calcium-Binding Proteins; 0 / Carcinoembryonic Antigen; 0 / Cyclin A; 0 / Cyclin D; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / Keratin-19; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Microfilament Proteins; 0 / TTF1 protein, human; 0 / alpha-Fetoproteins; 0 / beta Catenin; 0 / calponin; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


51. Mucha K, Foroncewicz B, Zieniewicz K, Nyckowski P, Krawczyk M, Cyganek A, Paczek L: Patient with liver epithelioid hemangioendothelioma treated by transplantation: 3 years' observation. Transplant Proc; 2006 Jan-Feb;38(1):231-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient with liver epithelioid hemangioendothelioma treated by transplantation: 3 years' observation.
  • Epithelioid hemangioendothelioma (EHE) is a rare neoplasm of vascular origin, but unknown etiology that occurs in the liver, lungs and other organs.
  • Surgical resection or liver transplantation (OLT) has been recommended after diagnosis.
  • We present a 30-year-old woman with primary HEHE of the liver treated by OLT in 2002.
  • Her medical history started 3 years prior when an abdominal ultrasound examination revealed multiple focal changes in the liver.
  • The histopathological diagnosis from a needle biopsy was carcinoma cholangiogenes desmoplasticum.
  • After 3 years observation the patient presented with good liver function and no signs of tumor recurrence.
  • We concluded that immunohistochemical staining for characteristic endothelial cell markers may facilitate the correct diagnosis of HEHE.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Treatment Outcome


52. Otsuka H, Graham MM, Kogame M, Nishitani H: The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med; 2005 Dec;19(8):691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology consisted of 8 adenocarcinomas, 8 squamous cell carcinomas, 4 adenoid cystic carcinomas, 4 carcinoma ex pleomorphic adenomas, 2 mucoepidermoid carcinomas, 2 poorly differentiated carcinomas, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma and 1 melanoma.
  • RESULTS: In the initial staging group, all 12 primary lesions (100%) showed positive FDG uptake (5 squamous cell carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 carcinoma ex pleomorphic adenoma, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma).
  • Three patients (25%) had FDG positive distant disease (liver, bone, lymph nodes); surgery was canceled and therapy changed to chemoradiation.
  • A second primary lesion was detected in one patient (4%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444995.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


53. Cho S, Lee JH, Cho SB, Yoon KW, Park SY, Lee WS, Park CH, Joo YE, Kim HS, Choi SK, Rew JS: Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma. Pathol Int; 2010 Mar;60(3):203-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma.
  • Caspase 8 and survivin are known as key molecules of apoptosis in hepatocellular carcinoma (HCC).
  • Promoter methylation of the caspase 8 and survivin gene was analyzed in 73 primary HCC using methylation-specific polymerase chain reaction.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Caspase 8 / genetics. DNA Methylation / genetics. Liver Neoplasms / genetics. Microtubule-Associated Proteins / genetics
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Apoptosis / genetics. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Count. Cell Proliferation. Chi-Square Distribution. Epigenesis, Genetic / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Prognosis. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403046.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


54. Sandhu SS, Symes A, A'Hern R, Sohaib SA, Eisen T, Gore M, Christmas TJ: Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int; 2005 Mar;95(4):522-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.
  • OBJECTIVE: To present our results on managing loco-regional recurrence of renal cell carcinoma (RCC) with surgical excision, as local recurrence at the site of a previous nephrectomy is resistant to both systemic therapy and radiotherapy.
  • The median (mean, range) age at the time of local recurrence was 57.9 (57.4, 28.9-71.7) years, and the median interval from primary surgery 2.22 (3.88, 0.27-14.46) years.
  • RESULTS: Two patients were deemed inoperable because of direct invasion of the great vessels and the liver by tumour.
  • The remaining 14 patients had recurrence in residual adrenal tissue (two), para-aortic nodes (three), para-caval nodes (two), retrocaval nodes (one), renal bed (six), liver, spleen and stomach (one each), and diaphragm (two).
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Nephrectomy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15705072.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem; 2010 Nov;58(11):1015-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum amyloid A (SAA) is an acute phase protein which is expressed primarily in the liver as a part of the systemic response to various injuries and inflammatory stimuli; its expression in ovarian tumors has not been described.
  • Expression was increased gradually as epithelial cells progressed through benign and borderline adenomas to primary and metastatic adenocarcinomas.
  • In addition, strong expression of SAA mRNA and protein was found in the ovarian carcinoma cell line OVCAR-3.
  • Finally, patients with ovarian carcinoma had high SAA serum levels, which strongly correlated with high levels of CA-125 and C-reactive protein.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Serum Amyloid A Protein / genetics. Serum Amyloid A Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. CA-125 Antigen / blood. Cell Line, Tumor. Female. Humans. Middle Aged. Neoplasm Metastasis. Ovary / cytology. Ovary / metabolism. Ovary / pathology. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]
  • [Cites] Ann Intern Med. 1979 Sep;91(3):383-90 [289303.001]
  • [Cites] Scand J Immunol. 1984 Mar;19(3):193-8 [6200925.001]
  • [Cites] Biochem Biophys Res Commun. 1991 May 15;176(3):1100-5 [2039494.001]
  • [Cites] DNA Cell Biol. 1991 Nov;10(9):651-61 [1755958.001]
  • [Cites] J Biol Chem. 1992 Feb 25;267(6):3862-7 [1740433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3186-90 [8159722.001]
  • [Cites] Genomics. 1994 Jan 15;19(2):228-35 [8188253.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):203-9 [7516407.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):650-60 [8080047.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1184-90 [7636186.001]
  • [Cites] Lab Invest. 1998 May;78(5):535-9 [9605178.001]
  • [Cites] J Histochem Cytochem. 1998 Dec;46(12):1377-84 [9815279.001]
  • [Cites] J Rheumatol. 1999 Apr;26(4):785-90 [10229397.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Eur J Immunol. 2005 Mar;35(3):718-26 [15724247.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 13;330(3):989-98 [15809093.001]
  • [Cites] Proteomics. 2005 Sep;5(14):3790-7 [16121334.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):105-14 [16385502.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5585-94 [17015746.001]
  • [Cites] Biomed Environ Sci. 2007 Feb;20(1):33-40 [17458139.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Apr 4;368(2):368-73 [18237545.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):579-85 [18243142.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95 [18028381.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2199-208 [19307507.001]
  • [Cites] Br J Cancer. 2009 Jul 21;101(2):335-41 [19536090.001]
  • [Cites] Cancer. 2010 Feb 15;116(4):843-51 [20041483.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88 [20082099.001]
  • [Cites] Eur Urol. 2010 May;57(5):859-66 [19747761.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):794-7 [3734116.001]
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):64-9 [10608507.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):405-8 [10679217.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1224-9 [11830469.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] J Histochem Cytochem. 1984 Mar;32(3):322-8 [6363521.001]
  • (PMID = 20713982.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Serum Amyloid A Protein; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2958134
  •  go-up   go-down


56. Brueckl WM, Schoeberl A, Wirtz RM, Murray S, Hahn EG, Wiest GH: Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol; 2008 Mar;3(3):314-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
  • A 37-year-old female never smoker with metastatic large cell carcinoma of the lung had a partial response to a second line palliative therapy with the EGF-R tyrosine kinase inhibitor erlotinib after platinum based first line therapy failed.
  • Molecular analysis of the primary and a liver metastasis did neither find any EGF-R mutation nor an EGF-R amplification.
  • However, both the primary and the metastasis showed an increased gene expression of vascular-endothelial growth factor-A in contrast to normal tissue, which was confirmed by immunohistochemistry.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / drug effects. Lung Neoplasms / metabolism. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adult. Erlotinib Hydrochloride. Fatal Outcome. Female. Follow-Up Studies. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Mutation. Protein Kinase Inhibitors / therapeutic use. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317076.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


57. Lin GH, Wang J, Li SH, Wang J, Xu L, Li SP: Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. Chin J Cancer; 2010 Apr;29(4):403-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma.
  • BACKGROUND AND OBJECTIVE: There are few studies about origins of regulatory T (Treg) cells increased in primary hepatocellular carcinoma (HCC) tissue.
  • Studies showed that Treg cells could be induced by transforming growth factor-beta1 (TGF-beta1), but the relation between TGF-beta1 expression and Treg cell infiltration is unclear in HCC tissue.
  • METHODS: Envision immunohistochemistry was used to detect the expression of TGF-beta1 and Foxp3 in 102 specimens of HCC tissue and paired adjacent non-tumor liver tissue.
  • Average Foxp3+ cell density in HCC was 2.98 cells/HP, but there was very few or no expression of Foxp3 in adjacent non-tumor liver tissue.
  • TGF-beta1 and Foxp3 expression had no correlations with tumor diameter, tumor capsule, liver cirrhosis, and so on.
  • The 5-year survival rate was not different between HCC tissues with high and low TGF-beta1 expression (P = 0.790); however, it was significantly lower in HCC tissues with high Treg cell infiltration than in those low infiltration (25% vs. 44%, P = 0.007).
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms. T-Lymphocytes, Regulatory / pathology. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Forkhead Transcription Factors / metabolism. Humans. Lymphocyte Count. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Survival Rate. Young Adult. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346216.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / alpha-Fetoproteins
  •  go-up   go-down


58. Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, Schirrmacher P, Klöppel G, Altevogt P, Schäfer H, Sebens Müerköster S: Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep; 2010 Oct;24(4):909-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma.
  • Recently, we identified L1CAM expression in pancreatic ductal adenocarcinoma (PDAC) cells accounting for chemoresistance and increased cell migration.
  • L1CAM expression was determined by immunohistochemistry in tissues of 123 patients including tissues of 110 primary PDACs, 15 lymph node metastases and 14 liver metastases.
  • The immunohistochemical analyses revealed L1CAM expression in 92.7% of primary PDACs, 80% of lymph node metastases and 100% of liver metastases.
  • Furthermore, its broad expression in primary tumors as well as in metastases of PDAC patients provide a rationale to further explore the value of L1CAM as a therapeutic target in the treatment of this highly malignant tumor.
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Neural Cell Adhesion Molecule L1 / biosynthesis. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811670.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


59. Kinoshita S, Hirano A, Komine K, Kobayashi S, Kyoda S, Takeyama H, Uchida K, Morikawa T, Nagase J, Sakamoto G: Primary small-cell neuroendocrine carcinoma of the breast: report of a case. Surg Today; 2008;38(8):734-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small-cell neuroendocrine carcinoma of the breast: report of a case.
  • Primary small-cell neuroendocrine carcinoma of the breast is a rare and aggressive neoplasm without an established treatment protocol because so few cases have been described.
  • We report a case of primary small-cell neuroendocrine carcinoma in a 31-year-old woman.
  • Core needle biopsy under ultrasonographic guidance revealed invasive carcinoma.
  • Definitive histopathological examination revealed primary small-cell neuroendocrine carcinoma.
  • Local and mediastinal recurrence with multiple liver metastases developed only 5 weeks after surgery.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):117-21 [14750249.001]
  • [Cites] Pathol Int. 1998 Sep;48(9):744-8 [9778114.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):64-6 [17270668.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):30-8 [17270663.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Dec;23 (4):691-6 [15743041.001]
  • [Cites] Am J Clin Oncol. 1995 Apr;18(2):133-8 [7534975.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):121-5 [6303551.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1231-8 [10976697.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 May;17(3):201-2 [15901010.001]
  • [Cites] Histopathology. 2001 Mar;38(3):277-8 [11260311.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4 Suppl):1341-4 [9990271.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):296-8 [10656743.001]
  • [Cites] Oncol Rep. 2004 Apr;11(4):825-31 [15010880.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):231-3 [15262362.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Hum Pathol. 2001 Jul;32(7):753-7 [11486176.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;404(2):213-21 [6091325.001]
  • [Cites] Breast. 2004 Apr;13(2):149-51 [15019697.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):888 [16873572.001]
  • [Cites] Pathol Int. 2000 Nov;50(11):914-8 [11107070.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(1):103-8 [1311484.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):775-8 [15976350.001]
  • (PMID = 18668318.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


60. Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, Kodama Y, Haga H, Ikai I, Chiba T: Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer; 2007 Feb 1;120(3):469-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activation-induced cytidine deaminase (AID) plays a role as a genome mutator in activated B cells, and inappropriate expression of AID has been implicated in the immunopathological phenotype of human B-cell malignancies.
  • Notably, we found that the transgenic mice overexpressing AID developed lung adenocarcinoma and hepatocellular carcinoma (HCC), suggesting that ectopic expression of AID can lead to tumorigenesis in epithelial tissues as well.
  • To examine the involvement of AID in the development of human HCC, we analyzed the AID expression and its correlation with mutation frequencies of the p53 gene in liver tissues from 51 patients who underwent resection of primary HCCs.
  • Only trace amounts of AID transcripts were detected in the normal liver; however, endogenous AID was significantly upregulated in both HCC and surrounding noncancerous liver tissues with underlying chronic hepatitis or liver cirrhosis (p < 0.05).
  • Most liver tissues with underlying chronic inflammation with endogenous AID upregulation already contained multiple genetic changes in the p53 gene.
  • In both hepatoma cell lines and cultured human primary hepatocytes, the expression of AID was substantially induced by TGF-beta stimulation.
  • Our findings suggest that the aberrant expression of AID is observed in human hepatocytes with several pathological settings, including chronic liver disease and HCC, which might enhance the genetic susceptibility to mutagenesis leading to hepatocarcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Cytidine Deaminase / genetics. Hepatocytes / metabolism. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Base Sequence. Cell Line, Tumor. Cells, Cultured. Enzyme Activation. Female. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Hepatitis, Viral, Human / physiopathology. Humans. Immunoblotting. Male. Middle Aged. Mutation / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transforming Growth Factor beta / pharmacology. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066440.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


61. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS: Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res; 2009;28:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is the most common tumor in the adult liver, with high relapse and mortality rates despite diverse treatment modalities.
  • METHODS: Frozen tumors and non-cancerous surrounding tissues from 120 patients with primary HCC were studied.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. Nicotinamide N-Methyltransferase / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cohort Studies. Disease-Free Survival. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1991 Nov;82(11):1277-83 [1836457.001]
  • [Cites] Clin Chim Acta. 1990 Jan 31;186(3):359-74 [2311261.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14835-40 [8182091.001]
  • [Cites] J Hepatol. 1994 Jan;20(1):138-42 [8201215.001]
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Oncol Res. 2004;14(10):491-9 [15559763.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):527-39 [15486044.001]
  • [Cites] J Pathol. 2005 Feb;205(3):377-87 [15682440.001]
  • [Cites] Toxicol Pathol. 2005;33(1):175-80 [15805069.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] J Urol. 2006 Nov;176(5):2248-54 [17070307.001]
  • [Cites] Exp Mol Med. 2006 Oct 31;38(5):455-65 [17079861.001]
  • [Cites] BMC Bioinformatics. 2007;8:66 [17326819.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 May;134(5):551-9 [17922140.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4814-20 [18676753.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6679-89 [18724390.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9167-75 [19010888.001]
  • [Cites] Physiol Genomics. 2001 Feb 7;5(1):21-33 [11161003.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4568-75 [11494152.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Feb;61(2):111-24 [11853016.001]
  • [Cites] Hepatology. 2002 May;35(5):1237-46 [11981774.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3939-44 [12124323.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S136-49 [12591191.001]
  • [Cites] Neurosci Lett. 2003 May 15;342(1-2):13-6 [12727306.001]
  • [Cites] Curr Mol Med. 2003 Sep;3(6):573-88 [14527088.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4990-6 [14557485.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):129-37 [15324696.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S51-5 [15508103.001]
  • [Cites] Gastroenterology. 1981 Oct;81(4):668-75 [7262512.001]
  • [Cites] Hepatology. 1988 Jan-Feb;8(1):65-8 [3338721.001]
  • [Cites] Arch Biochem Biophys. 1988 Feb 1;260(2):601-8 [2963591.001]
  • [Cites] Tumour Biol. 1994;15(1):7-16 [8146531.001]
  • (PMID = 19216803.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.1.1.1 / NNMT protein, human; EC 2.1.1.1 / Nicotinamide N-Methyltransferase
  • [Other-IDs] NLM/ PMC2657806
  •  go-up   go-down


62. Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X, Chen F: Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol; 2009 Feb;50(2):323-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer.
  • BACKGROUND/AIMS: Aberrant c-Jun N-terminal kinase (JNK) activation has been linked to hepatocellular carcinoma (HCC) in mouse models.
  • METHODS: The JNK activation, global gene expression, and the status of histone H3 methylations were measured in 31 primary human hepatocellular carcinoma (HCC) samples paired with the adjacent non-cancerous (ANC) tissues.
  • In addition, an association of JNK1 activation with the histone H3 lysines 4 and 9 tri-methylation was observed in the HCC tissues, which leads to an elevated expression of genes regulating cell growth and a decreased expression of the genes for cell differentiation and the p450 family members in HCC.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041150.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R01CA116697; United States / NCI NIH HHS / CA / R01 CA119028; United States / NCI NIH HHS / CA / R01 CA116697; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / 5R01CA119028
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Histones; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 8
  • [Other-IDs] NLM/ NIHMS546011; NLM/ PMC4417500
  •  go-up   go-down


63. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A: Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol; 2008 Jul;9(7):621-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiofrequency ablation is an accepted treatment for non-surgical patients with liver cancer.
  • Diagnoses included non-small-cell lung cancer (NSCLC) in 33 patients, metastasis from colorectal carcinoma in 53 patients, and metastasis from other primary malignancies in 20 patients.
  • Primary endpoints were technical success (defined as correct placement of the ablation device into all tumour targets with completion of the planned ablation protocol), safety (including identification of treatment-related complications and changes in pulmonary function), and confirmed complete response of tumours (according to modified Response Evaluation Criteria in Solid Tumors).
  • [MeSH-major] Carcinoma / surgery. Catheter Ablation. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome


64. Tang TJ, Vukosavljevic D, Janssen HL, Binda RS, Mancham S, Tilanus HW, Ijzermans JN, Drexhage H, Kwekkeboom J: Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum Pathol; 2006 Mar;37(3):332-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma.
  • Patients with hepatocellular carcinoma (HCC) are characterized by a weak T-cell response to their tumor, and chronic carriers of hepatitis B virus or hepatitis C virus have a poor T-cell response against the virus.
  • These inadequate T-cell responses may be due to insufficient activation of the T cells by dendritic cells (DCs).
  • Because lymph nodes (LNs) are the primary site of antigen-specific T-cell activation, we hypothesized that hepatic LNs of patients with HCC and/or chronic viral hepatitis might have aberrant compositions of their DC populations.
  • Patients with HCC and chronic viral hepatitis and patients with chronic viral hepatitis without HCC were compared with patients with liver inflammation of nonviral etiology and with organ donors with healthy livers.
  • The numbers of PDCs and mature MDCs in hepatic LNs of patients with chronic viral hepatitis did not differ from those of patients with liver inflammation of nonviral etiology nor from individuals with healthy livers.
  • However, hepatic LNs of patients with HBV or HCV infection complicated by HCC showed a 1.5-fold reduction in numbers of mature MDCs and a 4-fold increase in numbers of PDCs in their T-cell areas compared with those of patients with viral hepatitis only (P <.01).
  • This may be one of the causes of the inadequate T-cell response against HCC in these patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Dendritic Cells / pathology. Hepatitis B, Chronic / pathology. Hepatitis C, Chronic / pathology. Liver Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Count. Child. DNA, Viral / blood. Female. Hepacivirus / genetics. Hepacivirus / isolation & purification. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Humans. Male. Middle Aged. RNA, Viral / blood

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613328.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


65. Agarwal R, Levinson AW, Schowinsky J, Su LM: Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma. Urology; 2007 Nov;70(5):1008.e17-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma.
  • We report the case of a 39-year-old woman with a large right renal mass 20 cm in size with heterogeneous solid and cystic components as well as concurrent liver lesions suspicious for metastatic renal cell carcinoma.
  • Surgical extirpation of the renal mass and liver lesions was performed laparoscopically with the pathological analysis revealing a rare renal neoplasm--mixed epithelial and stromal tumor of the kidney--and adenomas of the liver.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


66. Nakanuma S, Tajima H, Okamoto K, Hayashi H, Nakagawara H, Onishi I, Takamura H, Kitagawa H, Fushida S, Tani T, Fujimura T, Kayahara M, Ohta T, Wakayama T, Iseki S, Harada S: Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2. Int J Oncol; 2010 Apr;36(4):793-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In primary malignant liver tumors, trypsinogen-immunoreactivity was present in 70% of intrahepatic cholangiocarcinoma (ICC) specimens, but absent in hepatocellular carcinoma (HCC) specimens.
  • The purpose of this study was to investigate the secretion of tumor-derived trypsin and the expression of its specific receptor, protease-activated receptor-2 (PAR-2), in ICC using cell lines and surgical specimens.
  • The expression of trypsinogen-1 mRNA was observed in three of four ICC cell lines, but none of three HCC cell lines.
  • Western blot analysis detected trypsinogen-1 in serum-free conditioned medium from one of the ICC cell lines positive for the mRNA.
  • PAR-2 mRNA and protein were observed in ICC cell lines.
  • [MeSH-major] Bile Duct Neoplasms / enzymology. Bile Ducts, Intrahepatic / enzymology. Cell Proliferation. Cholangiocarcinoma / enzymology. Receptor, PAR-2 / metabolism. Trypsin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / enzymology. Carcinoma, Hepatocellular / pathology. Culture Media, Serum-Free / metabolism. Dose-Response Relationship, Drug. Female. Fibroblasts / enzymology. Fibroblasts / pathology. Gabexate / pharmacology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Hep G2 Cells. Humans. Liver Neoplasms / enzymology. Liver Neoplasms / pathology. Male. Middle Aged. RNA, Messenger / metabolism. Serine Proteinase Inhibitors / pharmacology

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198321.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / RNA, Messenger; 0 / Receptor, PAR-2; 0 / Serine Proteinase Inhibitors; 4V7M9137X9 / Gabexate; EC 3.4.21.4 / PRSS1 protein, human; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


67. Mohan V, Jones RC, Drake AJ 3rd, Daly PL, Shakir KM: Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen. Thyroid; 2005 Feb;15(2):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen.
  • Papillary thyroid carcinoma (PTC) commonly metastasizes to cervical lymph nodes.
  • Well-differentiated thyroid carcinoma very rarely presents with metastases to the spleen.
  • This is the case of a 25-year-old man with a history of PTC (1.4 cm primary; no capsular invasion and negative lymph node metastases).
  • Contrast CT of the abdomen showed multiple low-attenuated heterogeneously enhancing splenic masses, normal liver and no intra-abdominal lymphadenopathy.
  • Despite the serum thyroglobulin of only 9.4 ng/mL, the finding of I(131) accumulation within solid splenic masses led to a preoperative diagnosis of thyroid carcinoma metastases.
  • Histopathologic analysis showed large littoral cell angiomas (LCA).
  • To our knowledge, this is the first case that describes multiple angiomas mimicking metastatic thyroid carcinoma to the spleen.
  • This is the first report of an association between LCA and thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / secondary. Hemangioma / pathology. Splenic Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. False Positive Reactions. Female. Humans. Iodine Radioisotopes. Tomography, X-Ray Computed. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Angioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753678.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


68. Fu XM, Yang QX, Shao CK, Feng ZY: [Expressions of h-TERT, c-myc, PCNA and cell apoptosis in liver carcinogenesis]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun;26(6):821-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of h-TERT, c-myc, PCNA and cell apoptosis in liver carcinogenesis].
  • OBJECTIVE: To investigate the expressions of human telomerase reverse transcriptase (h-TERT), c-myc, and proliferating cell nuclear antigen (PCNA) in chronic viral hepatitis (CVH), liver cirrhosis and primary hepatocellular carcinoma (HCC) and understand their possible role in liver carcinogenesis.
  • METHODS: Totally 157 liver disease specimens were collected, including 56 CVH, 52 liver cirrhosis and 49 primary HCC specimens.
  • In situ hybridization was performed on these specimens to examine the expressions of h-TRET and c-myc mRNA, and immunohistochemistry carried out for PCNA detection, with the cell apoptosis detected with in situ ending labeling.
  • RESULTS: In the CVH, liver cirrhosis and primary HCC specimens, h-TERT expression was detected at the frequencies of 11/56 (19.6%), 43/52 (82.7%) and 44/47 (93.6%), c-myc expression at 7/56 (12.5%), 21/52 (40.4%) and 26/47 (55.3%), with apoptotic index of (27.3-/+4.7)%, (16.5-/+2.6)% and (8.7-/+1.3)% and PCNA expression rate of (17.1-/+2.9)%, (49.3-/+7.8)% and (62.5-/+9.1)%, respectively.
  • CONCLUSION: Liver carcinogenesis may involve increased h-TERT, c-myc, and PCNA expressions and suppressed cell apoptosis.
  • [MeSH-major] Apoptosis. Liver Neoplasms / pathology. Proliferating Cell Nuclear Antigen / biosynthesis. Proto-Oncogene Proteins c-myc / genetics. Telomerase / genetics
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Transformation, Neoplastic. Female. Hepatitis B, Chronic / genetics. Hepatitis B, Chronic / metabolism. Hepatitis B, Chronic / pathology. Humans. Immunohistochemistry. Liver Cirrhosis / genetics. Liver Cirrhosis / metabolism. Liver Cirrhosis / pathology. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793609.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


69. Burri E, Steuerwald M, Cathomas G, Mentha G, Majno P, Rubbia-Brandt L, Meier R: Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol; 2006 Apr;18(4):437-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver.
  • Liver-cell adenomas are benign lesions of the liver occurring predominantly in young women.
  • Hepatocellular carcinomas in most of the cases arise in a cirrhotic liver during the fifth or sixth decade.
  • Tests for chronic liver diseases were negative.
  • The tumour was surgically removed and a hepatocellular carcinoma arising within a liver-cell adenoma in a non-cirrhotic liver was found.
  • Malignant transformation of liver-cell adenoma has only been reported in a few case reports.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538118.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


70. Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P: Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol; 2008 Feb;13(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
  • BACKGROUND: Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease.
  • METHODS: In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Liver Neoplasms / drug therapy. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein Kinases / metabolism. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):649-53 [14991931.001]
  • [Cites] Liver Transpl. 2004 Oct;10(10):1301-11 [15376305.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1843-52 [16767220.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):986-91 [9744316.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1392-3 [12176410.001]
  • [Cites] Radiology. 2004 Jan;230(1):300-1; author reply 301-2 [14695404.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1420-5 [15770715.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):226-30 [9705862.001]
  • [Cites] Transpl Int. 2005 Jan;18(1):89-94 [15612989.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Liver Transpl. 2001 Jun;7(6):473-84 [11443573.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4442-5 [15483011.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):789-93 [15868910.001]
  • [Cites] Acta Oncol. 2005;44(5):496 [16118084.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3818-22 [16799623.001]
  • (PMID = 18307022.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


71. Xu J, Chen X: Expression of twist gene in primary liver cancer. J Huazhong Univ Sci Technolog Med Sci; 2007 Dec;27(6):668-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of twist gene in primary liver cancer.
  • In order to investigate the possibility of overexpression of Twist in primary liver cancer (PLC), the Twist expression was detected by using immunohistochemical analysis and RT-PCR assay in 45 patients with PLC.
  • Control tissues were obtained from 9 patients with liver hemangioma.
  • In noncancerous adjacent areas and control liver tissues, the expression of Twist was 57.8% and 22.2% respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Nuclear Proteins / genetics. Twist-Related Protein 1 / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1906-13 [12702582.001]
  • [Cites] Nat Genet. 1997 Jan;15(1):42-6 [8988167.001]
  • [Cites] Dev Biol. 1995 Nov;172(1):280-92 [7589808.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 3;300(1):178-81 [12480539.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):2294-9 [15545268.001]
  • [Cites] Hum Mutat. 2005 Jun;25(6):550-6 [15880747.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7416-28 [11585922.001]
  • [Cites] Nucleic Acids Res. 1987 Apr 24;15(8):3439-53 [3106932.001]
  • [Cites] Clin Genet. 2004 May;65(5):396-9 [15099347.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12 (6):488-96 [15864483.001]
  • [Cites] Genes Dev. 1995 Mar 15;9(6):686-99 [7729687.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Cell. 2003 Jan 24;112(2):169-80 [12553906.001]
  • [Cites] J Clin Invest. 2002 Sep;110(5):633-41 [12208864.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Dev Biol. 1997 Sep 15;189(2):205-14 [9299114.001]
  • [Cites] Genes Dev. 1999 Sep 1;13(17 ):2207-17 [10485844.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • (PMID = 18231738.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Twist-Related Protein 1
  •  go-up   go-down


72. Chalermchai T, Suwanrusme H, Chantranuwat P, Voravud N, Sriuranpong V: Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005. Asia Pac J Clin Oncol; 2010 Jun;6(2):111-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005.
  • OBJECTIVE: The aim of this study was to review cases of extra-pulmonary small cell carcinoma (EPSCC), including their clinical manifestations and treatment outcomes.
  • The most common primary sites were the gastrointestinal organs and the nasal cavity.
  • EPSCC of pancreas demonstrated a favorable clinical outcome with treatment, whereas primary EPSCC of the liver, esophagus and rectum had an aggressive natural history and a poor response to treatment.
  • CONCLUSION: Our report suggests that EPSCC may have a different biology from that of pulmonary small cell carcinoma.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / pathology. Urogenital Neoplasms / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20565423.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Number-of-references] 15
  •  go-up   go-down


73. Nan KJ, Ruan ZP, Jing Z, Qin HX, Wang HY, Guo H, Xu R: Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis. World J Gastroenterol; 2005 Jan 14;11(2):228-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.
  • AIM: To evaluate the expression of fragile histidine triad (FHIT) gene protein, product of a candidate tumor suppressor, and to investigate the relationship between FHIT, cell apoptosis and proliferation, and pathological features of primary hepatocellular carcinoma (HCC).
  • METHODS: Forty-seven HCC and ten normal liver specimens were collected during surgical operation between 2001 and 2003.
  • FHIT and proliferating cell nuclear antigen (PCNA) expression were detected by immunohistochemistry, and apoptotic level was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay on the tissue sections.
  • RESULTS: All normal liver tissues showed a strong expression of FHIT, whereas 28 of 47 (59.6%) carcinomas showed a significant loss or absence of FHIT expression (P = 0.001).
  • Apoptotic incidence in advanced TNM stage carcinoma and those with positive FHIT expression was higher than that in early stage carcinoma (P = 0.030) and in those with negative FHIT expression (P = 0.044) respectively.
  • The proliferating potential of hepatocellular carcinoma was associated with FHIT expression (P = 0.016) and the aggressive feature (P = 0.019).
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Apoptosis / genetics. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cell Division / genetics. Genes, Tumor Suppressor. Histidine / genetics. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Female. Humans. Liver / physiology. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Reference Values

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15633221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 4QD397987E / Histidine; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4205407
  •  go-up   go-down


74. Ward SC, Thung SN, Lim KH, Tran TT, Hong TK, Hoang PL, Jang JJ, Park YN, Abe K: Hepatic progenitor cells in liver cancers from Asian children. Liver Int; 2010 Jan;30(1):102-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic progenitor cells in liver cancers from Asian children.
  • BACKGROUND/AIMS: Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the two most common primary malignant liver tumours in children.
  • We investigated the morphology and staining patterns of primary liver tumours in Asian children.
  • Paediatric HCC has a morphology different from adult HCC, sometimes resembling HB, and a larger proportion of paediatric tumours have progenitor cell features.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatoblastoma / pathology. Hepatocytes / pathology. Liver Neoplasms / pathology. Stem Cells / pathology
  • [MeSH-minor] Adolescent. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Child. Child, Preschool. DNA, Viral / analysis. Female. Hepacivirus / genetics. Hepacivirus / isolation & purification. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Humans. Immunohistochemistry. Infant. Keratin-19 / metabolism. Male. Proto-Oncogene Proteins c-kit / metabolism. RNA, Viral / analysis. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793197.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DNA, Viral; 0 / Keratin-19; 0 / RNA, Viral; 0 / tumor-associated antigen GA733; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


75. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Huang JH, Gao F, Gu YK, Li WQ, Lu LW: Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol; 2007 Dec 28;13(48):6593-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization.
  • AIM: To prospectively evaluate the efficacy and safety of partial splenic embolization (PSE) combined with transcatheter hepatic arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma (HCC).
  • METHODS: Fifty patients suffering from primary HCC associated with hypersplenism caused by cirrhosis were randomly assigned to 2 groups: group A receiving PSE combined with TACE (n = 26) and group B receiving TACE alone (n = 24).
  • RESULTS: Prior to treatment, there was no significant difference in sex, age, Child-Pugh grade, tumor diameter, mass pathology type and peripheral blood cell counts between the 2 groups.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Embolization, Therapeutic / methods. Hepatic Artery. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Blood Cell Count. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18161933.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4611302
  •  go-up   go-down


77. Kim KH, Kim SH, Kim SH, Back JH, Park MJ, Kim JM: Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation. J Korean Med Sci; 2006 Dec;21(6):1064-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the expressions of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in thyroid neoplasms in a Korean population, we studied a total of 154 cases: papillary carcinoma of classical type (PTC), 86; follicular adenoma (FA), 21; follicular carcinoma (FC), 35; medullary carcinoma (MC), 3; undifferentiated carcinoma (UC), 5; and Hurthle cell neoplasm (HN), 4.
  • In PTC, COX-2 and iNOS were significantly overexpressed in patients over 45 yr of age (p=0.029, p=0.041), and iNOS expression was increased in patients with a large primary tumor (p=0.028).
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Thyroid. 1999 Feb;9(2):113-7 [10090309.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G688-96 [11518681.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] Ann Clin Lab Sci. 2001 Oct;31(4):325-48 [11688844.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):358-63 [11788675.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):238-42 [11889377.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):546-51 [11939728.001]
  • [Cites] Prostate. 2002 Nov 1;53(3):232-40 [12386924.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):331-40 [12665651.001]
  • [Cites] Histopathology. 2003 May;42(5):492-7 [12713627.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1604-10 [12738712.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):434-9 [12828608.001]
  • [Cites] Korean J Intern Med. 2003 Dec;18(4):225-9 [14717230.001]
  • [Cites] Histopathology. 2004 May;44(5):490-7 [15139997.001]
  • [Cites] Br J Pharmacol. 1993 Mar;108(3):833-7 [7682140.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1352-4 [7509718.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):727-30 [7531613.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2625-34 [9169492.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] BJU Int. 2000 Oct;86(6):736-41 [11069387.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):303-8 [11196178.001]
  • [Cites] Antioxid Redox Signal. 2001 Apr;3(2):231-48 [11396478.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):S35-9 [11442675.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2445-51 [9278337.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31138-48 [9388267.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Laryngoscope. 1999 Jan;109(1):148-52 [9917057.001]
  • (PMID = 17179688.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2721930
  •  go-up   go-down


78. Kidd M, Modlin IM, Mane SM, Camp RL, Eick G, Latich I: The role of genetic markers--NAP1L1, MAGE-D2, and MTA1--in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol; 2006 Feb;13(2):253-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Candidate marker gene expression (nucleosome assembly protein 1-like 1 [NAP1L1], melanoma antigen D2 [MAGE-D2], and metastasis-associated protein 1 [MTA1]) identified by Affymetrix transcriptional profiling was examined by QRT-PCR in SIC, liver, and lymph node (LN) metastases, colorectal carcinomas, and healthy tissues.
  • Immunohistochemical expression levels of MTA1 were analyzed quantitatively by a novel automated quantitative analysis in a tissue microarray of 102 gastrointestinal carcinoids and in a breast/prostate carcinoma array.
  • Increased levels (P < .05) were identified in both liver and LN metastases.
  • MAGE-D2 and MTA1 were increased (P < .05) in primary tumors and metastases and overexpressed in carcinomas.
  • Automated quantitative analysis demonstrated the highest levels of MTA1 immunostaining in malignant primary SICs and in metastases to the liver and LN.
  • These were significantly increased (P < .02) compared with nonmetastatic primary tumors.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoid Tumor / genetics. Cell Cycle Proteins / metabolism. Histone Deacetylases / metabolism. Intestinal Neoplasms / genetics. Intestine, Small. Nuclear Proteins / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Female. Genetic Markers. Humans. Male. Middle Aged. Nucleosome Assembly Protein 1. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424981.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-097050
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Genetic Markers; 0 / MAGED2 protein, human; 0 / NAP1L1 protein, human; 0 / Nuclear Proteins; 0 / Nucleosome Assembly Protein 1; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


79. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol; 2006 Jan 7;12(1):54-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.
  • AIM: To assess subcellular localization of KL-6 mucin and its clinicopathological significance in colorectal carcinoma as well as metastatic lymph node and liver tissues.
  • METHODS: Colorectal carcinoma tissues as well as metastatic lymph node and liver tissues were collected from 82 patients who underwent colorectomy or hepatectomy.
  • RESULTS: Of the 82 colorectal carcinoma patients, 6 showed no staining, 29 showed positive staining only in the apical membrane, and 47 showed positive staining in the circumferential membrane and/or cytoplasm.
  • Statistical analysis between clinicopathological factors and subcellular localization of KL-6 mucin showed that KL-6 localization in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion (P = 0.0003), lymphatic invasion (P<0.0001), lymph node metastasis (P<0.0001), liver metastasis (P = 0.058), and advanced histological stage (P<0.0001).
  • Positive staining was observed in all metastatic lesions tested as well as in the primary colorectal carcinoma tissues.
  • CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Mucin-1. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1988 Mar 25;263(9):4215-22 [3346246.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5450-4 [16222735.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):455-9 [10675475.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L625-9 [10710536.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):425-30 [11819805.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1183-90 [12054500.001]
  • [Cites] Histopathology. 2003 Mar;42(3):239-45 [12605643.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1113-23 [2045853.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2318-24 [1559234.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):171-6 [8667623.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):67-71 [15782996.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):203-16 [3411786.001]
  • (PMID = 16440417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  • [Other-IDs] NLM/ PMC4077483
  •  go-up   go-down


80. Jelski W, Zalewski B, Szmitkowski M: The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in liver cancer. Dig Dis Sci; 2008 Sep;53(9):2550-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in liver cancer.
  • BACKGROUND: Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), which are most abundant in the liver, are the main enzymes involved in ethanol and acetaldehyde metabolism.
  • AIMS: The purpose of this study was to compare the activity of ADH isoenzymes and ALDH between liver carcinoma cells and healthy hepatocytes.
  • PATIENTS: Samples were taken from 44 liver cancer patients (19 drinkers, 25 nondrinkers).
  • Seventeen patients had primary liver tumors and 27 had metastatic liver tumors.
  • CONCLUSION: Differences in the activities of total ADH, ALDH and class I ADH isoenzyme between cancer liver tissues and healthy hepatocytes might be a factor in ethanol metabolism disorders, which can intensify carcinogenesis.
  • [MeSH-major] Alcohol Dehydrogenase / metabolism. Aldehyde Dehydrogenase / metabolism. Aldehyde Oxidoreductases / metabolism. Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Biopsy. Case-Control Studies. Female. Humans. Isoenzymes / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Recent Dev Alcohol. 1998;14:7-40 [9751941.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9247-51 [1409630.001]
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Dig Dis Sci. 2007 Feb;52(2):531-5 [17211707.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):137S-143S [11391063.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Ann Clin Biochem. 1993 Mar;30 ( Pt 2):146-51 [8385433.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Histochem Cell Biol. 1999 May;111(5):391-7 [10403118.001]
  • [Cites] Cancer Lett. 1993 Feb;68(2-3):177-83 [8443790.001]
  • [Cites] J Clin Lab Anal. 2003;17(3):93-6 [12696080.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):87-107, vi [11218921.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):1085-105 [8143977.001]
  • [Cites] Alcohol. 2005 Apr;35(3):195-203 [16054981.001]
  • [Cites] Clin Liver Dis. 2005 Feb;9(1):1-35 [15763227.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):69-85 [11218920.001]
  • [Cites] Pancreas. 2007 Aug;35(2):142-6 [17632320.001]
  • [Cites] Carcinogenesis. 1985 Dec;6(12):1683-7 [4064245.001]
  • [Cites] Dig Dis Sci. 2002 Jul;47(7):1554-7 [12141816.001]
  • (PMID = 18224440.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.1.1.1 / alcohol dehydrogenase IV; EC 1.1.1.284 / formaldehyde dehydrogenase (glutathione); EC 1.2.- / Aldehyde Oxidoreductases; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


81. Karamitopoulou E, Cioccari L, Jakob S, Vallan C, Schaffner T, Zimmermann A, Brunner T: Active caspase 3 and DNA fragmentation as markers for apoptotic cell death in primary and metastatic liver tumours. Pathology; 2007 Dec;39(6):558-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active caspase 3 and DNA fragmentation as markers for apoptotic cell death in primary and metastatic liver tumours.
  • AIMS: The induction of tumour cell death by apoptosis is a major goal of cancer therapy and the in situ detection of apoptosis in tumour tissue has become an important diagnostic parameter.
  • Different apoptosis detection methods assess distinct biochemical processes in the dying cell.
  • The aim of this study was to compare the immunohistochemical detection of active caspase 3 and single-stranded DNA in primary and metastatic liver tumours as markers of apoptotic cell death.
  • METHODS: We studied detection of active caspase 3 and single-stranded DNA in 20 primary hepatocellular carcinomas (HCC) and 20 liver metastases from colorectal carcinomas (CRC) using immunohistochemistry on paraffin sections.
  • CONCLUSION: The sensitivity of apoptosis detection using immunohistochemistry for active caspase 3 and single-stranded DNA may be tumour cell type dependent.
  • [MeSH-major] Apoptosis. Carcinoma, Hepatocellular / enzymology. Carcinoma, Hepatocellular / genetics. Caspase 3 / metabolism. Colorectal Neoplasms / enzymology. DNA Fragmentation. Liver Neoplasms / enzymology. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Cell Line, Tumor. DNA, Neoplasm. DNA, Single-Stranded. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged


82. Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G: First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation; 2010 Mar 27;89(6):733-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation.
  • We present the preliminary results of a prospective nonrandomized trial concerning the first HIV patient series receiving RAPA monotherapy after liver transplantation (LT).
  • METHODS: Since June 2003, 14 HIV patients have received cadaveric donor LT due to end-stage liver disease (ESLD) associated or not associated with hepatocellular carcinoma, scored by the model for ESLD system.
  • Patients were assessed using the following criteria for HIV characterization: CD4 T-cell count more than 100/mL and HIV-RNA levels less than 50 copies/mL.
  • Primary immunosuppression was based on calcineurin inhibitors (CI), whereas switch to RAPA monotherapy occurred in cases of CI complications or Kaposi's sarcoma.
  • All patients were affected by ESLD, which was associated with hepatocellular carcinoma in seven patients.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. HIV Infections / drug therapy. HIV-1 / drug effects. Hepatitis B / surgery. Hepatitis C / surgery. Immunosuppressive Agents / therapeutic use. Liver Transplantation. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. Graft Rejection / etiology. Graft Rejection / prevention & control. Graft Survival. Hepacivirus / genetics. Hepatitis B virus / genetics. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prospective Studies. RNA, Viral / blood. Time Factors. Treatment Outcome. Viral Load


83. Huang JH, Wu PH, Gu YK, Zhang FJ, Li CX, Gao F, Zhang L, Fan WJ, Li CJ: [Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization]. Ai Zheng; 2006 Aug;25(8):1003-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization].
  • BACKGROUND & OBJECTIVE: 70-90% of patients of primary hepatocellular carcinoma (PHC) are associated with liver cirrhosis, portal hypertension and hypersplenism.
  • The treatment of PHC is usually hampered by low or slow recovery of blood cell counts.
  • RESULTS: Satisfactory effects were achieved in PSE combined with TACE group in terms of correction of blood cell counts compared with cases treated with TACE alone.
  • CONCLUSION: PSE associated with TACE is safe and effective for the treatment of patients with PHC associated with liver cirrhosis, portal hypertension and hypersplenism.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Hypersplenism / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Blood Cell Count. Embolization, Therapeutic / methods. Female. Hepatic Artery. Humans. Iodized Oil. Male. Splenic Artery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965683.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8001-40-9 / Iodized Oil
  •  go-up   go-down


84. Morimoto O, Nagano H, Miyamoto A, Fujiwara Y, Kondo M, Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S, Dono K, Umeshita K, Nakamori S, Sakon M, Monden M: Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood. Surg Today; 2005;35(12):1033-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood.
  • PURPOSE: Intra- and extrahepatic recurrence is common, even after curative resection for hepatocellular carcinoma (HCC), suggesting preoperative or intraoperative tumor cell dissemination.
  • Reverse transcription - polymerase chain reaction (RT-PCR) for alpha-fetoprotein (AFP) is used to detect circulating liver cancer cells.
  • The detection of AFP mRNA was significantly correlated with extrahepatic metastasis after primary surgery, and a shorter disease-free survival time (P = 0.0245 each).
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Liver Neoplasms / blood. Neoplasm Recurrence, Local / blood. RNA, Messenger / blood. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Bone Marrow / metabolism. Case-Control Studies. Chi-Square Distribution. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Polymerase Chain Reaction. Prognosis. Prospective Studies. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1993 Jul;18(1):47-53 [7686879.001]
  • [Cites] Lancet. 1996 Mar 9;347(9002):649-53 [8596379.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):415-23; discussion 423-5 [7574923.001]
  • [Cites] Hepatology. 1994 Dec;20(6):1418-25 [7527002.001]
  • [Cites] Arch Surg. 2000 Dec;135(12):1456-9 [11115352.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):527-32 [11179482.001]
  • [Cites] Arch Surg. 2000 Feb;135(2):213-8 [10668884.001]
  • [Cites] Dig Dis Sci. 2000 Jul;45(7):1376-82 [10961717.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1749-56 [1919627.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4021-7 [10632334.001]
  • [Cites] Hepatology. 1990 Oct;12 (4 Pt 1):680-7 [1698703.001]
  • [Cites] Hepatology. 1994 Apr;19(4):889-94 [8138262.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):768-75 [7875479.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):381-6 [10228826.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):919-25 [8884314.001]
  • [Cites] Hepatology. 2002 Apr;35(4):853-60 [11915031.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2772-80 [7954236.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1503-9 [15307868.001]
  • [Cites] Lancet. 1992 Sep 19;340(8821):685-9 [1381801.001]
  • [Cites] Ann Surg. 1997 Jul;226(1):43-50 [9242336.001]
  • [Cites] Am J Surg Pathol. 1989 Dec;13(12):1064-7 [2556944.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):818-21 [12378622.001]
  • [Cites] Br J Cancer. 1997;76(5):628-33 [9303362.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Apr;16(4):445-51 [11354284.001]
  • [Cites] Br J Cancer. 1997;75(6):928-33 [9062418.001]
  • [Cites] Arch Surg. 2002 Jan;137(1):94-9 [11772225.001]
  • [Cites] Life Sci. 1998;62(21):1973-84 [9619847.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):469-72 [8751199.001]
  • [Cites] Cancer. 1992 Nov 1;70(9):2263-7 [1327495.001]
  • [Cites] Surgery. 2002 Jan;131(1):34-43 [11812961.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):500-4 [11118315.001]
  • [Cites] Langenbecks Arch Surg. 2001 Mar;386(2):118-23 [11374044.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1534-9 [1403032.001]
  • [Cites] Cancer. 1995 May 1;75(9):2214-9 [7536120.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1504-9 [1347253.001]
  • (PMID = 16341483.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  •  go-up   go-down


85. Cioppa T, Marrelli D, Neri A, Caruso S, Pedrazzani C, Malagnino V, Pinto E, Roviello F: A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy. Eur J Cancer Care (Engl); 2007 Sep;16(5):453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy.
  • Primary small-cell carcinoma (SmCC) of the stomach is a rare neoplasm with a poor prognosis and unclear histogenesis: to date, only 50 cases, including ours, have been reported in the literature.
  • In this paper, the authors present a clinical case and the surgical treatment of an adult with a SmCC of the stomach associated with gastric adenocarcinoma.
  • After laparotomy, a large neoplasm with locoregional extension and multiple liver metastases were found.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / secondary. Kidney Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760934.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Sun YL, Yin SY, Xie HY, Zhou L, Xue F, Wu LM, Gao F, Zheng SS: Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol; 2008 Aug;23(8 Pt 1):1280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity.
  • BACKGROUND AND AIM: Recent investigations demonstrate that adult stem cells may be targets for malignant transformation and that the stem-like cells in diseased livers possess the capacity of tumorigenicity in animal models.
  • The aim of this study is to examine expression patterns of stem-cell markers in hepatitis B virus-associated cirrhotic livers and hepatocellular carcinomas (HCC), and to investigate the stem-like cell capacity of tumorigenicity in these tissues.
  • METHODS: Twenty surgically resected HCCs and corresponding adjacent tissues as well as 10 cirrhotic liver tissues were collected and immunohistochemical staining were performed to detect the expression of CD34, Thy-1, CD133, and c-kit.
  • Then the non-cancerous tissues were transplanted into immunodeficient mice and the characteristics of the cells from primary tissue cultures were explored in vitro.
  • RESULTS: Immunohistochemical analysis characterized different expression patterns of stem-cell markers among these tissues.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Hepatitis B, Chronic / complications. Liver Cirrhosis / metabolism. Liver Neoplasms / metabolism. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466286.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • But the eventual development of liver metastases which are the most common cause of mortality still argues for an aggressive surgical approach in the early stages of the disease.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


88. Iwamoto A, Ikeguchi M, Matsumoto S, Hukumoto Y, Inoue M, Ozaki T, Ataka M, Tanida T, Endo K, Katano K, Hirooka Y: Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma. Tumori; 2006 Mar-Apr;92(2):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma.
  • AIMS AND BACKGROUND: In several neoplastic diseases including hepatocellular carcinoma (HCC) immunosuppression is correlated with disease stage, progression and outcome.
  • The present study analyzed the correlation between local immune responses and COX-2 gene expression levels in patients with primary HCCs.
  • The COX-2 gene expression levels were quantified by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and compared with the CD8+ T cell densities detected by immunohistochemistry.
  • The CD8+ T cell density in COX-2-expressing tumors (6.1 cells/high-power field (HPF), x200 magnification) was suppressed compared with that in non-COX-2-expressing tumors (13.6 cells/HPF, P = 0.009).
  • CONCLUSIONS: Elevation of the tumor COX-2 level is correlated with the suppression of local immune responses in HCCs, suggesting that COX-2 plays a role in early tumor recurrence in the residual liver in patients after HCC resection.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / immunology. Cyclooxygenase 2 / metabolism. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD8-Positive T-Lymphocytes / immunology. Disease-Free Survival. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724692.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


89. Ispas C, Yu J, Tarantino DR, Lara JF: Pathologic quiz case: a 44-year-old woman with a tubulovillous adenoma of the colon and liver and bone lesions. Small cell (neuroendocrine) carcinoma of the colon with metastasis and an associated, overlying villous adenoma. Arch Pathol Lab Med; 2005 Mar;129(3):412-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic quiz case: a 44-year-old woman with a tubulovillous adenoma of the colon and liver and bone lesions. Small cell (neuroendocrine) carcinoma of the colon with metastasis and an associated, overlying villous adenoma.
  • [MeSH-major] Adenoma, Villous / diagnosis. Bone Neoplasms / secondary. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / secondary. Colonic Neoplasms / diagnosis. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737043.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Nagao Y, Sata M: High incidence of multiple primary carcinomas in HCV-infected patients with oral squamous cell carcinoma. Med Sci Monit; 2009 Sep;15(9):CR453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of multiple primary carcinomas in HCV-infected patients with oral squamous cell carcinoma.
  • We investigated the association among oral squamous cell carcinoma (OSCC), multiple primary cancers (MPCs), insulin resistance and HCV infection.
  • MATERIAL/METHODS: Upper gastrointestinal tract examination and determination of the presence of HCV infection were routinely done for 60 primary OSCC patients.
  • In HCV-infected cases, 10 MPCs with patients, hepatocellular carcinoma (HCC) was the most common outcome (5 cases), whereas gastric cancer was the most common outcome (6 cases) in non-HCV-infected 11 MPCs.
  • CONCLUSIONS: HCV infection was strongly associated with the occurrence of MPCs as well as primary OSCC.
  • In patients with HCV infection, it is important to clinically examine organs other than the liver.
  • [MeSH-major] Carcinoma, Squamous Cell. Hepacivirus / metabolism. Hepatitis C. Mouth Neoplasms. Neoplasms, Multiple Primary / etiology. Neoplasms, Multiple Primary / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Insulin Resistance. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors


91. Kang MH, Kim SN, Kim NK, Park YI, Kim YW, Ryu KW, Lee JH, Lee JS, Park SR: Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy. Ann Surg Oncol; 2010 Dec;17(12):3163-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy.
  • BACKGROUND: We conducted the current study to investigate the clinical outcomes of metastatic gastric carcinoma (MGC) patients who experienced gastrointestinal (GI) perforation during palliative chemotherapy and to examine the prognostic factors associated with survival after perforation.
  • Patients with perforation at the primary gastric site were more likely to have ulcerative gastric cancer lesion (90.5 vs. 40.0%, P = 0.034) or gastric tumor bleeding (28.6 vs. 0%, P = 0.298), and less likely to have Bormann type IV (14.3 vs. 60.0%, P = 0.062), than patients with perforation at nongastric sites.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Signet Ring Cell / drug therapy. Intestinal Perforation / chemically induced. Liver Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Palliative Care. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585878.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Otegbayo JA, Yakubu A, Akere A, Igetei R, Aje AO: Quality of life among primary liver cell carcinoma patients in Ibadan, Nigeria. Afr J Med Med Sci; 2005 Mar;34(1):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life among primary liver cell carcinoma patients in Ibadan, Nigeria.
  • A descriptive prospective study was conducted to evaluate the quality of life of patients with primary liver cell carcinoma at the University College Hospital, Ibadan, Nigeria.
  • [MeSH-major] Carcinoma / psychology. Liver Neoplasms / psychology. Quality of Life. Sickness Impact Profile
  • [MeSH-minor] Adult. Aged. Female. Hospitals, University. Humans. Male. Middle Aged. Nigeria. Patient Satisfaction. Prognosis. Prospective Studies. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15971554.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


93. Shi M, Qian S, Chen WW, Zhang H, Zhang B, Tang ZR, Zhang Z, Wang FS: Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin Exp Immunol; 2007 Feb;147(2):277-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.
  • To investigate whether hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells (MoDC) could mount a T cell response in hepatocellular carcinoma (HCC) patients associated with chronic HBV infection, peripheral blood mononuclear cells (PBMCs) from 36 HBV-associated HCC patients were induced into MoDC and pulsed with hepatitis B core antigen (HBcAg) and hepatitis B surface antigen (HBsAg), alone and in combination.
  • MoDC pulsed with HBcAg or HBsAg + HBcAg also had the strongest ability to stimulate autologous T cell proliferation and intracellular interferon (IFN)-gamma production.
  • HBcAg- or HBsAg + HBcAg-pulsed MoDC could also induce HBV core peptide-specific CD8(+) T cell proliferation determined by tetramer staining.
  • In addition, the antigen-pulsed MoDC were found to have a stronger capacity to produce IL-12 and induce T cell response in vitro for patients with higher alanine transaminase (ALT) levels than those with lower ALT levels, indicating that antigen pulse could substantially reverse the impaired function of MoDC in primary HCC patients with active chronic hepatitis B.
  • In conclusion, HBV antigen-pulsed MoDC from HCC patients with chronic hepatitis B could induce HBV-specific T cell response in vitro.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Dendritic Cells / immunology. Hepatitis B Antigens / immunology. Hepatitis B, Chronic / immunology. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / blood. CD8-Positive T-Lymphocytes / immunology. Cell Differentiation / immunology. Cell Proliferation. Cells, Cultured. Female. Humans. Immunophenotyping. Interferon-gamma / biosynthesis. Lymphocyte Activation / immunology. Male. Middle Aged. Monocytes / immunology. T-Lymphocytes / immunology. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Mar;6(3):332-6 [10700237.001]
  • [Cites] J Immunol. 2006 May 1;176(9):5644-51 [16622034.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Apr;15(4):431-6 [10824889.001]
  • [Cites] Annu Rev Immunol. 2001;19:65-91 [11244031.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):739-47 [16785573.001]
  • [Cites] Nat Immunol. 2000 Sep;1(3):199-205 [10973276.001]
  • [Cites] Blood. 2001 May 15;97(10):3171-6 [11342445.001]
  • [Cites] Immunology. 2001 May;103(1):90-7 [11380696.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6451-8 [11522640.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):406-14 [11900226.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):537-41 [11819824.001]
  • [Cites] J Exp Med. 2002 May 6;195(9):1089-101 [11994415.001]
  • [Cites] J Virol. 2002 Sep;76(17):8609-20 [12163580.001]
  • [Cites] Cancer Immunol Immunother. 2002 Dec;51(11-12):637-44 [12439609.001]
  • [Cites] Int J Mol Med. 2003 Feb;11(2):169-74 [12525872.001]
  • [Cites] Hepatology. 2003 Jul;38(1):4-13 [12829979.001]
  • [Cites] Immunology. 2003 Aug;109(4):487-95 [12871214.001]
  • [Cites] Clin Exp Immunol. 2004 Mar;135(3):462-6 [15008979.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1118-29 [15014185.001]
  • [Cites] World J Gastroenterol. 2004 Apr 15;10(8):1146-51 [15069715.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1461-3 [15070799.001]
  • [Cites] Curr Drug Targets Infect Disord. 2004 Jun;4(2):93-101 [15180457.001]
  • [Cites] Int J Mol Med. 2004 Aug;14(2):295-9 [15254781.001]
  • [Cites] J Gen Virol. 2004 Oct;85(Pt 10):2829-36 [15448344.001]
  • [Cites] Res Virol. 1993 Jan-Feb;144(1):75-80 [8446782.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):3025-33 [9185527.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):170-5 [9252092.001]
  • [Cites] J Immunol. 1997 Aug 15;159(4):2001-8 [9257867.001]
  • [Cites] Eur J Immunol. 1997 Dec;27(12):3135-42 [9464798.001]
  • [Cites] Nat Med. 1998 Mar;4(3):328-32 [9500607.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4520-9 [9794377.001]
  • [Cites] J Hepatol. 1999 May;30(5):755-64 [10365798.001]
  • [Cites] J Hepatol. 1999 Aug;31(2):323-31 [10453947.001]
  • [Cites] Virology. 1999 Sep 1;261(2):165-72 [10497102.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 2):2532-8 [15538202.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):637-46 [15622448.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Feb;20(2):234-42 [15683426.001]
  • [Cites] World J Gastroenterol. 2005 Mar 28;11(12):1806-8 [15793869.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2005 Jan 26;85(4):248-52 [15854486.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jul;131(7):429-38 [15818505.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1117-32 [10751335.001]
  • (PMID = 17223969.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Antigens; 82115-62-6 / Interferon-gamma; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC1810470
  •  go-up   go-down


94. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, Graeter T: Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer; 2009 Apr;64(1):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma.
  • The prognostic relevance of blood vessel invasion (BVI) in non-small cell lung carcinoma (NSCLC) remains controversial, as is the question of whether its finding should influence therapeutic decisions after an R0 resection.
  • All had been treated by potentially curative surgical resection of the primary tumor and systematic lymphadenectomy.
  • Thus 31.2% of the patients developed distant metastases by hematogenous spread (to the brain, bones, lung, adrenal, and liver, in descending order of frequency), mostly within two years of surgery.
  • Adenocarcinomas showed a strong tendency to be associated with a poorer prognosis than squamous cell carcinomas, probably because of their more frequent involvement of blood vessels.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790545.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


95. Hervieu V, Lombard-Bohas C, Dumortier J, Boillot O, Scoazec JY: Primary acinar cell carcinoma of the liver. Virchows Arch; 2008 Mar;452(3):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the liver.
  • We report a case of acinar cell carcinoma primary to the liver.
  • The tumor was diagnosed in a 35-year-old woman complaining of abdominal pain and asthenia; serum alpha-fetoprotein (AFP) levels were increased at 6,000 IU/mL; imaging studies showed a hypervascular mass located in the left lobe of the liver.
  • The final diagnosis, based on histological, immunohistochemical, and ultrastructural arguments, was extra-pancreatic acinar cell carcinoma, primary to the liver.
  • This unusual lesion is likely to be the result of an abnormal differentiation pathway involving a transformed multipotential progenitor cell.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Liver / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Treatment Outcome. alpha 1-Antitrypsin / analysis. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2001 Mar;128(6):871-81 [11222142.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S94-112 [17486055.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] Indian J Med Sci. 1979 Jun;33(6):157-9 [521108.001]
  • [Cites] Surg Today. 2007;37(8):704-7 [17643220.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1524-9 [16224221.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jul-Aug;9(4):312-5 [16944990.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):203-9 [10981872.001]
  • [Cites] Hum Pathol. 2002 May;33(5):569-73 [12094386.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Trends Endocrinol Metab. 2003 Dec;14(10):460-6 [14643061.001]
  • [Cites] Hepatogastroenterology. 1992 Jun;39(3):282-6 [1380476.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31950-7 [12775714.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):449-51 [12055683.001]
  • (PMID = 18193278.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / alpha 1-Antitrypsin; 0 / alpha-Fetoproteins
  •  go-up   go-down


96. Kuo FY, Swanson PE, Yeh MM: Pancreatic acinar tissue in liver explants: a morphologic and immunohistochemical study. Am J Surg Pathol; 2009 Jan;33(1):66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar tissue in liver explants: a morphologic and immunohistochemical study.
  • BACKGROUND: Pancreatic acini-like tissue is occasionally seen in the liver.
  • To gain further insight into this issue, we performed a pathologic and immunohistochemical study in liver explants to identify pancreatic acinar tissue.
  • DESIGN: A total of 382 liver explants transplanted from 1995 to 2000 were examined.
  • RESULTS: Sixteen (4.2%) of 382 liver explants contained pancreatic acini-like tissue.
  • Fifteen of these were cirrhotic livers due to cryptogenic cirrhosis (n=1), primary biliary cirrhosis (n=3), primary sclerosing cholangitis (n=1), chronic hepatitis C-related cirrhosis (n=5), and cirrhosis with hepatitis C and hepatocellular carcinoma (n=5).
  • CONCLUSIONS: Our results collectively indicate that pancreatic acini-like tissue in liver represent aggregates of pancreatic acinar cells admixed with small intra-acinar terminal ductules.
  • [MeSH-major] Cell Transdifferentiation / physiology. Choristoma / etiology. Choristoma / pathology. Liver Diseases / pathology. Pancreas
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987542.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y: Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol; 2008 Apr;134(4):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Pim-3, a member of the proto-oncogene Pim family with serine/threonine kinase activity was aberrantly expressed in cancerous lesions of endoderm-derived organs such as liver, pancreas, and colon.
  • METHODS: Pim-3 expression was immunohistochemically examined on the tissue microarrays containing primary (n = 285) and metastastic (n = 37) sites of gastric carcinomas, in comparison with adenoma (n = 48) and non-cancerous mucosa (n = 84).
  • RESULTS: Pim-3 expression was enhanced in adenoma (64.6%) and metastasis sites of gastric carcinoma (73.0%), to a lesser degree in primary sites of gastric carcinoma (39.3%) when compared to non-cancerous mucosa (13.1%, p < 0.0001).
  • Pim-3 expression levels were higher in intestinal-type than diffuse-type gastric carcinoma (p = 0.018).
  • Furthermore, patients with Pim-3 positive gastric cancer, showed a lower cumulative survival rate than those with Pim-3 negative gastric cancer (p = 0.014) and Pim-3 positive was also identified as an independent prognostic factor for gastric carcinoma patients (p = 0.006).
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / analysis. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Tissue Array Analysis. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3 [14571786.001]
  • [Cites] J Surg Oncol. 2007 Aug 1;96(2):95-101 [17443727.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):209-18 [15540201.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):376-80 [15900596.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):201-5 [11756242.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):241-52 [15799824.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):499-516 [12134615.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(11):3897-908 [12748291.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4536-44 [14982870.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):242-8 [15543611.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):321-8 [17270021.001]
  • [Cites] Pathol Int. 2003 Oct;53(10 ):659-66 [14516315.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):647-51 [10492641.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):507-18 [14655756.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):16-26 [11197247.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16535-43 [9632723.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12):3359-69 [10369676.001]
  • [Cites] Cell Oncol. 2005;27(4):215-23 [16308470.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2618-24 [16200194.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6741-7 [16818649.001]
  • [Cites] Croat Med J. 2007 Apr;48(2):207-17 [17436385.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] Hepatogastroenterology. 2006 Jul-Aug;53(70):484-90 [16995446.001]
  • (PMID = 17876606.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / PIM3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


98. Basile J, Caldwell S, Nolan N, Hammerle C: Clear cell hepatocellular carcinoma arising 25 years after the successful treatment of an infantile hepatoblastoma. Ann Hepatol; 2010 Oct-Dec;9(4):465-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell hepatocellular carcinoma arising 25 years after the successful treatment of an infantile hepatoblastoma.
  • Primary liver tumors in children are rare with hepatoblastoma (HB) being the most common malignancy.
  • Clear cell carcinoma, a variant of hepatocellular carcinoma (HCC), is another rare tumor of the liver that tends to affect adults.
  • We describe the diagnosis and management of the only known documented case of a primary clear cell HCC arising twenty-five years after the patient was successfully treated with chemotherapy and surgical resection for a malignant HB as an infant.
  • Further knowledge of liver tumorigenesis will help elucidate the complicated genetic, molecular, and environmental factors involved in the development of these two rare hepatic malignancies.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Hepatoblastoma / drug therapy. Hepatoblastoma / surgery. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy. Combined Modality Therapy. Genetic Predisposition to Disease / genetics. Humans. Magnetic Resonance Imaging. Male. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057168.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


99. Khoshbaten M, Naderpour M, Mohammadi G, Alipoor SH, Estakhri R, Fazeli Z: Epidemiology of esophageal lesions in patients with head and neck squamous cell carcinoma. Asian Pac J Cancer Prev; 2010;11(4):863-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of esophageal lesions in patients with head and neck squamous cell carcinoma.
  • BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is disturbing because of its aggressive clinical path and high mortality rate.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Esophagitis / epidemiology. Head and Neck Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking. Coloring Agents. Esophagoscopy. Female. Humans. Iodides. Iran. Male. Middle Aged. Risk Factors. Smoking


100. Stelow EB, Debol SM, Stanley MW, Mallery S, Lai R, Bardales RH: Sampling of the adrenal glands by endoscopic ultrasound-guided fine-needle aspiration. Diagn Cytopathol; 2005 Jul;33(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) has proven to be a valuable modality for the primary diagnosis and staging of gastrointestinal, and perigastrointestinal malignancy.
  • Aside from assessing thoracic and abdominal lymph nodes and the liver for metastases, EUS can assess and sample the adrenal glands, which are frequently involved by metastatic disease, but can also harbor benign primary neoplasms.
  • The utility of cell block immunohistochemistry (IHC) in these cases was reviewed.
  • Material for cell block was present in 21 cases, and IHC was used in 3 cases.
  • Final diagnoses were as follows: cortical tissue consistent with cortical adenoma (19), metastatic adenocarcinoma (3), pheochromocytoma (1), and adrenal cortical carcinoma (1).
  • Diagnostic tissue is easily obtained, including material for cell block IHC, which allows definitive diagnosis in cases that present difficult differential diagnoses.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Adrenocortical Carcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pheochromocytoma / diagnosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc
  • (PMID = 15945088.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement